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ABSTRACT 
 
ACTIVATABLE FLUOROPHORES FOR THE MOLECULAR IMAGING OF 
CYTOSOLIC PHOSPHOLIPASE A2 IN BREAST CANCER 
Michael Gerard Chiorazzo 
E. James Delikatny, Ph.D. 
 
Breast cancer is the most commonly diagnosed cancer in women and the number two 
cause of cancer associated death.  Surgery is the first line of defense in treating breast 
cancer and the success of surgery has been shown to predict the probability of cancer 
reoccurrence.  Near Infrared (NIR) fluorescence guided surgery offers the potential to 
increase the accuracy of surgical resection by the use of fluorescence imaging agents 
targeted towards cancer.  Cytosolic Phospholipase A2 (cPLA2) activity is enhanced in 
triple negative breast cancer and is associated with resistance to therapy in luminal-like 
cancers.  The goal of this work is to develop activatable fluorophores targeted towards 
cPLA2 and evaluate their use for the molecular imaging of breast cancer in order to 
determine their potential as contrast agents for NIR fluorescence guided surgery.  A 
series of tricyclic fluorophores were caged through esterification with fatty acids.  
Arachidonic acid was utilized to generate cPLA2 selective probes and palmitic acid was 
used to generate control probes.  In vitro, probes were shown to activate in the presence 
of purified PLA2 and results were used to identify the most promising probe: DDAO 
arachidonate.  Cellular fluorescence spectroscopy and microscopy showed DDAO 
arachidonate activated in breast cancer cell lines expressing cPLA2, where control probe 
did not.  Modulation of cPLA2 activity through inhibition, induction, and genetic 
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knockdown, resulted in corresponding changes in fluorescence generation.  In a panel of 
breast cancer cell lines, cPLA2 expression, varied based on molecular subtype and 
correlated with DDAO arachidonate activation.  Finally, DDAO arachidonate, when 
painted onto human triple negative tumor mouse xenografts, resulted in selective 
activation of tumor but not surrounding healthy tissue.  Together, these results indicate 
DDAO arachidonate is a useful agent for measuring cPLA2 activity in both breast cancer 
cells and tumors and may offer the potential to aid in the fluorescence guided surgery of 
triple negative breast cancer. 
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CHAPTER 1: Introduction 
1.1 Breast Cancer 
In women, breast cancer is the most frequently diagnosed cancer and the second 
highest cause of cancer related death (DeSantis et al. 2014).  Breast cancer has been 
shown to be not one disease, but an umbrella term for numerous cancer subtypes.  
Extensive study on the molecular basis of breast cancer subtypes has led to the 
elucidation of varying genetic signatures.  This has driven the development of molecular 
based therapeutics, which targets these genetic signatures in each subtype.  The growth of 
targeted therapeutics in addition to increased screening of the general population has 
likely been the cause of decreased mortality rates in breast cancer patients (Berry et al. 
2005).  Despite this, surgical resection through either mastectomy or breast conserving 
surgery in combination with radiation therapy remains the standard for primary treatment 
(DeSantis et al. 2014).  The accuracy of surgery, as defined by the presence of positive 
margins in tissue histology, is a significant predictor for local recurrence and metastasis, 
suggesting complete removal of the primary tumor is necessary for enhancing the 
probability of relapse free survival (Singletary 2002).   
Estrogen receptor (ER) positive is the most frequently diagnosed form of breast 
cancer (Haque et al. 2012).  Commonly referred to as luminal-like, cancers expressing 
estrogen receptor can be classified as luminal A or luminal B.  Luminal A has the most 
favorable prognosis of all breast cancer subtypes and is associated with the highest 
probability of relapse free and overall survival (Prat and Perou 2011).  It is generally 
defined as having high levels of ER and/or progesterone receptor (PR) with no expression 
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of the HER2/Neu oncogene, low Ki67 staining (a standard marker of proliferation), and a 
low histological grade (Eroles et al. 2012).  For breast cancer, histological grade is 
determined in accordance with the Nottingham grading system which evaluates tumors 
based on tubule formation, nuclear grade, and mitotic rate (Edge and Compton 2010).  
Luminal B breast cancer has high amounts of ER and/or PR along with either expressing 
the HER2/Neu oncogene or having high staining for Ki67 with a high histological grade.  
Unlike luminal A, luminal B breast cancer has lower rates of relapse free and overall 
survival (Prat and Perou 2011).  In addition to surgery and radiation therapy, common 
adjuvant treatment of luminal-like breast cancer consists of hormonal therapy with 
selective estrogen receptor modifiers (SERMs).  One of the most commonly used SERMs 
is tamoxifen, a prodrug whose biologically active metabolites result in competitive 
antagonism of ER (Osborne 1998). 
HER2-type breast cancer is defined as expressing the HER2/Neu oncogene 
without expression of ER or PR (Eroles et al. 2012).  The HER2/Neu gene encodes for a 
transmembrane tyrosine kinase receptor that falls within the epidermal growth factor 
receptor (EGFR) family (Ross et al. 2003).  Activation of EGFR enhances homo and 
hetero-dimerization resulting in autophosphorylation and the initiation of various major 
biological signaling cascades (Normanno et al. 2006).  Overexpression of HER2/Neu has 
been shown to occur in 20-30% of breast cancers and has fueled the development of anti-
HER2/Neu therapies (Slamon et al. 1987).  Most notable is the monoclonal antibody, 
trastuzumab, which is selective for the extracellular portion of the HER2 transmembrane 
protein (Hudis 2007).  The anti-cancer activity of trastuzumab may result from a 
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combination of mechanisms including decreasing HER2 dimerization, increasing 
receptor endocytosis and subsequent degradation, preventing the cleavage and release of 
the extracellular domain, and immune activation resulting in cancer cell death 
(Valabrega, Montemurro, and Aglietta 2007).  Regardless, significant efficacy has been 
shown in HER2-type breast cancer patients when used in combination with traditional 
chemotherapeutics (O'Sullivan et al. 2015). 
Basal-like is a subtype of breast cancer which does not have elevated ER, PR, or 
HER2/Neu. Because of this, it is often referred to as triple negative breast cancer and has 
the lowest probability of relapse free and overall survival (Eroles et al. 2012). No 
molecular based therapeutics exist for this subtype and only traditional chemotherapy in 
addition to surgery and radiation therapy is possible. Basal-like breast cancer has a high 
response rate to pre-surgical neoadjuvant chemotherapy (Lehmann et al. 2011).  Despite 
this, high rates of recurrence and metastasis result in lower probability of relapse free and 
overall survival, with less than 30% of basal-like patients surviving 5 years.   
A further complication to this model of genetic variation and subsequent 
treatment of breast cancer is the increasing understanding of tumor heterogeneity.  
Heterogeneity within breast cancer can arise both spatially, in which several populations 
of cells with varying genetic signatures are present within the same tumor, or temporally, 
in which the genetic signatures of cells change with time in the primary tumor and 
metastatic lesions (Zardavas et al. 2015). Certain basal-like tumors have been shown to 
contain distinct populations of luminal-like progenitors (Lim et al. 2009).  In addition, 
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differences in expression of ER, PR, and HER2 have been seen between primary tumor 
and metastatic lesions (Aurilio et al. 2014).   
It is likely that tumor heterogeneity, in addition to the limited number of 
molecular therapeutics, contributes to the problem of breast cancer resistance, 
reoccurrence, and metastasis.  Because of therapeutic limitations, surgical resection 
through either mastectomy or breast conserving surgery in combination with radiation 
therapy remains the primary treatment for breast cancer, being performed in 95% of 
cases.  Improvement of surgical resection efficiency would likely have a high benefit on 
survival. 
Near Infrared (NIR) fluorescence guided surgery has recently emerged as a 
powerful technique to aid surgeons during tumor resection.  By administering 
fluorophores, which either accumulate or activate specifically in cancerous tissue, 
surgeons can use fluorescence as a guide for the discernment of tumor margins (Nguyen 
and Tsien 2013).  To date, several studies have shown the ability of NIR fluorescence 
guided surgery to improve surgical resections in patients (Shinoda et al. 2003, van Dam 
et al. 2011, Day et al. 2013, Stummer et al. 2006, Keating et al. 2016, Judy et al. 2015).  
However, the pool of fluorescence contrast agents under study remains small and the 
most well studied agents rely primarily on the enhanced permeability and retention effect 
(EPR) of tumors.  In order to expand the capabilities and efficiency of this technique, 
new contrast agents targeted towards distinct molecular features of cancer are urgently 
needed.  
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1.2 Phospholipases 
Phospholipases are a class of enzyme responsible for the catabolism of 
phospholipids within biological membranes.  First discovered for their role as a lytic 
agent in snake venom, phospholipases have since been shown to have numerous 
biological functions including digestion, membrane re-modeling (necessary for cell 
division, motility, and vesicular trafficking), and the generation of bioactive signaling 
molecules (Burke and Dennis 2009, Rocha et al. 2014). In cancer, increased cell division 
through membrane remodeling along with the production of bioactive signaling 
molecules that promote cancer progression have been linked to phospholipase activation. 
Figure 1.1. Overview of phospholipase activity.  PLA1 and PLA2 cleave at the sn-1 and sn-2 ester bond 
respectively to generate lysophosphatidic acid and a free fatty acid.  PLC cleaves at the glycerol-phosphate 
bond to release phosphatidic acid and a free head group.  PLD cleaves at the head group-phosphate bond to 
generate DAG and a phosphorylated head group. 
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Phospholipases are grouped into four major categories based on the location in 
which they hydrolyze phospholipids (Figure 1.1).  Phospholipase D hydrolyzes the bond 
linking the head group to the phosphate moiety releasing a free head group in addition to 
phosphatidic acid.  Phospholipase D has been found elevated in several cancers including 
breast, colon, gastric, and kidney (Park et al. 2012).  It is generally thought to promote 
cancer progression through the activation of RAS and mTOR by phosphatidic acid (Zhao 
et al. 2007, Fang et al. 2001).  Phospholipase C is perhaps the most well-known 
phospholipase for its role in signaling.  Phospholipase C hydrolyses the glycerophosphate 
bond of phospholipids releasing diacylglycerol (DAG) and a phosphorylated head group.  
When phospholipase C acts on phosphatidylinositides, inositol-1,4,5-triphosphate (IP3) is 
released.  IP3 and DAG have been extensively studied for their role in signaling and in 
relation to cancer.  IP3 leads to release of calcium from intracellular stores leading to 
modulation of numerous enzymes which are dependent on calcium binding (Berridge 
2009).  DAG is the principal activator of protein kinase C (PKC), which has been shown 
to promote the progression of cancer (Griner and Kazanietz 2007).  Finally, 
phospholipase A1 and A2 (PLA1 and PLA2, respectively) are responsible for the release 
of a lysophospholipid and a free fatty acid from, respectively, either the sn-1 or sn-2 
position of the glycerol backbone.  Lysophospholipids are potent activators of cancer and 
can stimulate mobilization and subsequent invasion (Xu et al. 1995).  Free fatty acids can 
be stored in lipid droplets, recycled into biological membranes, metabolized via beta 
oxidation, or used to synthesize downstream signaling molecules (Boren and Brindle 
2012, Delikatny et al. 2011).  Arachidonic acid release serves as the precursor to 
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eicosanoid signaling molecules, which have been shown to have numerous roles in 
cancer progression (Wang and Dubois 2010). 
PLA2 can be further sub-classified into sixteen groups, each representing PLA2 
enzymes with distinct biological functions.  Secreted phospholipase A2 (sPLA2) 
enzymes (which include groups I, II, III, V, and X) are found in the extracellular space, 
are the largest family of phospholipases, and the first to be discovered.  Though large in 
number, they are smallest in size, typically ranging from 14-18 kDa (with the exception 
of group III). sPLA2 enzymes are dependent on calcium for activity and serve a range of 
functions including digestion, activity in inflammatory processes, and microbial 
protection (Burke and Dennis 2009).  sPLA2 has been shown to play a role in several 
diseases including rheumatoid arthritis, atherosclerosis, and cancer (Dennis et al. 2011). 
Calcium independent phospholipase (iPLA2, group VI) is an intracellular PLA2 
which does not require calcium for its activity (Burke and Dennis 2009).  iPLA2β is the 
most well studied iPLA2 family member.  Due to its calcium independent actions it has 
been long thought to function in homeostatic membrane remodeling (Winstead, Balsinde, 
and Dennis 2000).  Recently it has been suggested that iPLA2 may also be active in 
several signaling processes.  iPLA2 has been implicated in the development of diabetes, 
Barth syndrome, and NBIA/neuroaxonal dystrophy (Dennis et al. 2011). 
Platelet activating factor-acetyl hydrolase (PAF-AH, group VII) acts on PAF to 
release acetate from the sn-2 position.  PAF-AH is a secreted enzyme that associates with 
LDL and HDL in the human plasma (Tjoelker et al. 1995).  Increased PAF-AH is 
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associated with an increased risk of coronary disease, stroke, and mortality (Oei et al. 
2005).  Lysosomal phospholipase A2 (LPLA2) (group XV) localizes to lysosomal 
compartments of cells where it acts to degrade lysosomal phospholipids.  LPLA2 is 
highly expressed in alveolar macrophages (Abe et al. 2004).  Adipose-specific 
phospholipase A2 (group XVI) is expressed to high levels in white adipose tissue 
(Duncan et al. 2008).  Adipose-specific phospholipase A2 has been shown to also possess 
PLA1 activity and functions to release stored fatty acids for energy conversion through 
beta oxidation.   
Cytosolic phospholipase A2 (cPLA2, group IV) is a class of phospholipases that 
are primarily considered signaling enzymes.  Like iPLA2, cPLA2 is an intracellular 
phospholipase and resides in the cytosol until activated (Dennis et al. 2011).  cPLA2α, 
the most studied isoform, was first found in platelets and neutrophils, but is now known 
to be ubiquitously expressed in all mammalian tissue.  This 85 kDa protein contains a C2 
calcium binding domain and a catalytic domain containing a unique catalytic dyad 
instead of the catalytic triad seen in α/β hydrolases (Dessen et al. 1999).  Unlike other 
PLA2 enzymes, cPLA2α displays substrate specificity for arachidonic acid at the sn-2 
position (Murakami et al. 2011).  Since the discovery of cPLA2α, two additional human 
isoforms have been found (along with three murine isoforms).  cPLA2β is a ubiquitous 
phospholipase, and contains a C2 domain and a catalytic domain similar to cPLA2α.  
Unlike cPLA2α, cPLA2β has relatively low substrate specificity and general 
phospholipase activity.  cPLA2γ is expressed to a high degree in heart and skeletal 
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muscle, has low substrate specificity, and lacks a C2 domain allowing it to act 
independent of calcium (Dennis et al. 2011). 
1.3 cPLA2 and Cancer 
cPLA2α, henceforth referred to as cPLA2, is activated during calcium release 
from cytosolic stores.  The binding of calcium to the C2 domain of cPLA2 results in 
translocation to the perinuclear membrane where it acts upon arachidonic acid-containing 
phospholipids.  In addition to calcium, cPLA2 activity can be enhanced by 
phosphorylation through mitogen-activated protein (MAP).  Ser505 phosphorylation 
promotes membrane binding of hydrophobic residues surrounding the active site.  This 
allows for cPLA2 to remain bound to the membrane and active after the cytosolic 
calcium concentration returns to baseline (Das et al. 2003). An additional residue, Ser727 
is targeted by a heterotetramer (A2t) of p11 and annexin A2, which when bound to 
Ser727 disrupts cPLA2 membrane binding and inhibits activity (Tian et al. 2008).  
Phosphorylation of Ser727 prevents targeting by the inhibitory A2t tetramer and allows 
full activation of cPLA2.  In addition, phosphorylation of Ser515 by calmodulin-
dependent kinase II has also been shown to result in cPLA2 activation (Muthalif et al. 
2001). Independent of phosphorylation, several other associations result in the retainment 
of cPLA2 on the membrane. Phosphatidylinositol 4,5-bis phosphate (PIP2) has been 
found to bind residues within the catalytic domain and promote cPLA2 activity (Tucker 
et al. 2009). Finally, ceramide-1-phosphate (C1P) has been found to be required for 
translocation of cPLA2 through association with a β-groove in the C2 domain (Lin et al. 
1993, Mosior, Six, and Dennis 1998, Subramanian et al. 2005, Lamour et al. 2009).  
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cPLA2 functions as a signaling agent due to its ability to release free arachidonic 
acid. Free arachidonic acid is an important central mediator in inflammatory and 
replicative processes. Arachidonic acid can be acted upon by cytochrome P450 (CYPs), 
lipoxygenase, or cyclooxygenase to generate prostaglandins and eicosanoids, a large 
family of bioactive molecules involved in autocrine and paracrine signaling (Figure 1.2) 
(Wang and Dubois 2010).  In addition to homeostatic maintenance, eicosanoids are 
involved in a wide range of functions including vasodilation and constriction of vascular 
smooth muscle, aggregation and declumping of platelets, contraction of uterine smooth 
muscle, bone resorption, ovulation, pain response, fever generation, and inflammation 
(Funk 2001).  Dysregulation of eicosanoids has been implicated in several diseases 
including rheumatoid arthritis, hypertension, atherosclerosis, and cancer. 
Figure 1.2. Eicosanoid Signaling Pathway.   
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CYPs are best known for their involvement in the detoxification of compounds in 
the liver.  Blockage of these enzymes can result in the prolonged half-life of drugs, 
resulting in increased delivery of many compounds, including anticancer drugs 
(Panigrahy et al. 2010).  In contrast, certain anticancer prodrugs rely on the actions of 
CYPs and increasing their activity may increase efficacy (Lu, Chen, and Waxman 2009).  
In addition, the action of CYPs on endogenous substrates such as arachidonic acid are 
thought to play a role in tumor progression (Nebert and Dalton 2006).  Arachidonic acid 
metabolism through CYPs occurs through either the -hydroxylase pathway, resulting in 
the formation of hydroxyeicosatetraenoic acids (HETEs), or the epoxygenase pathway, 
resulting in formation of epoxyeicosatrienoic acids (EETs) (Panigrahy et al. 2010). 20-
HETE, the primary metabolite of the -hydroxylase pathway, has pro-inflammation and 
pro-angiogenic associations.  Inhibition of CYPs in the 20-HETE pathway has been 
shown to reduce tumor growth in triple negative breast cancer, mouse tumor xenografts 
(Borin et al. 2014).  EETs have also been shown to promote angiogenesis and have a role 
in epithelial cell proliferation (Harris et al. 1990).  CYP J2J, involved in EET synthesis 
has been found to be elevated in 77% of carcinomas (Jiang et al. 2005). 
Lipoxygenase activity results in the formation of HETEs and leukotrienes, which 
have been shown to have several roles in cancer (Wang and Dubois 2010).  LTB4 has 
been shown to be increased in colon and prostate cancer (Larre et al. 2008, Dreyling et al. 
1986).  Pancreatic cancer has increased LTB4 receptors, and administration of LTB4 
increases growth of pancreatic cancer cells (Hennig et al. 2002). LTA4 hydrolase has 
been shown to be elevated in esophageal cancer through analysis of patient tissue (Chen 
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et al. 2003).   Inhibition of LTA4 hydrolase in a rat model of esophageal cancer resulted 
in reduced cancer growth (Chen et al. 2003).   
The cyclooxygenase pathway is the most well studied pathway for arachidonic 
acid metabolism in relation to cancer.  Cyclooxygenase has two isoforms (COX-1 and -
2), with COX-1 being considered a constitutively active housekeeping enzyme whereas 
COX-2 is inducible in response to various stimuli (Simmons, Botting, and Hla 2004).  In 
cancer, overexpression of COX-2 has been shown in numerous cancers including colon, 
prostate, head and neck, lung, cervical, and breast cancer (Eberhart et al. 1994, Gupta et 
al. 2000, Khuri et al. 2001, Kulkarni et al. 2001, Lin et al. 2002, Subbaramaiah et al. 
2002).  Inhibition of cyclooxygenases with nonsteroidal anti-inflammatory drugs 
(NSAIDs) has shown some ability to prevent and treat cancer (Thun, Henley, and Patrono 
2002).   
Cyclooxygenase acts on arachidonic acid to generate prostaglandin H2, which is 
then further converted into the prostaglandins and thromboxanes.  Prostaglandins have 
been shown to have varying activity in cancer progression.  PGE2 is well known for its 
association with cancer, promoting proliferation, angiogenesis, metastasis, and evasion of 
apoptosis (Greenhough et al. 2009).  In contrast, increased production of PGD2 results in 
decreased growth of cancer (Park et al. 2007).  It has been hypothesized that this is not 
through the direct activity of PGD2 but due to either the association of the PGD2 product, 
15dPGJ2, with PPARγ or through depletion of PGE2 through increased PGD2 synthesis 
(Sertznig et al. 2007, Wang and Dubois 2010). 
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The expression of cPLA2 and COX2 has been shown to be positively correlated 
in colorectal cancer, likely due to the requirement of free arachidonic acid for 
prostaglandin production (Panel et al. 2006).  Unsurprisingly, cPLA2 has been shown to 
be overexpressed in a number of cancers and associated with cancer development (Hong 
et al. 2001, Meyer et al. 2004, Murakami et al. 2011).  In breast cancer, cPLA2 activity 
correlates with molecular subtype (Caiazza, Harvey, and Thomas 2010).  In both 
established cell lines and patient tissue, cPLA2 mRNA is significantly elevated in basal-
like versus luminal-like breast cancer (Caiazza et al. 2011).  In agreement with these 
observations, 
1
H nuclear magnetic resonance (NMR) analysis of glycerophosphocholine, 
generated through the hydrolysis of phosphatidylcholine by cPLA2, is markedly elevated 
in basal-like cancers compared to luminal-like cancers (Moestue et al. 2010).  In luminal-
like breast cancer, it has been shown that estradiol-2 can lead to rapid phosphorylation 
and subsequent activation of cPLA2 through an EGFR mediated mechanism (Caiazza, 
Harvey, and Thomas 2010).  Furthermore, a correlation between cPLA2 mRNA and 
EGFR mRNA has been shown in both basal-like and luminal-like breast cancers (Caiazza 
et al. 2011).  It has been suggested that cPLA2 activation through EGFR is a possible 
mechanism for the development of resistance to estrogen receptor therapy.  In support of 
this claim, it has been shown that luminal-like patients with higher levels of cPLA2 have 
a significantly lower rate of overall survival (Caiazza et al. 2011).  As a result, cPLA2 is 
emerging as a useful biomarker for the differentiation of breast cancer subtypes and a 
predictor for the likelihood of resistance generation to estrogen receptor therapy.  
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1.4 Molecular Imaging and Cancer 
There are a number of platforms for cancer imaging currently in clinical and 
preclinical use, including X-ray computed tomography (CT), ultrasound, magnetic 
resonance imaging/spectroscopy (MRI/MRS), positron emission tomography (PET), and 
fluorescence.  Depending on the technique employed, anatomical, physiological, and/or 
molecular information about cancer can be obtained.  Imaging may be performed with the 
use of exogenous contrast agents or may rely on the distinction of endogenous features 
visualized through energy/tissue interfaces.  Molecular imaging of cancer offers the 
potential to provide phenotypic and genotypic information in addition to anatomical 
tumor location.  Real-time knowledge of the molecular characteristics of tumors allows 
for the determination, monitoring, and possible alteration of treatment protocols 
(Weissleder 2006).  In addition, tools that can assess cancer signatures in in vivo models 
can fuel anticancer drug design and evaluation (Willmann et al. 2008).   
 CT, ultrasound, and MRI are all widely used in clinical practice.  Traditionally, 
these modalities have been used for anatomical imaging.  Although this remains their 
primary use, research in the use of these techniques for molecular imaging has been of 
increased interest.  Smart or targeted contrast agents have been utilized in these 
modalities to image molecular characteristics unique to cancer. As an example, gold 
nanoparticles conjugated to a prostate specific membrane antigen (PMSA) RNA aptamer 
were used to image PMSA expressing prostate cancer using CT (Popovtzer et al. 2008).  
Αvβ3 integrin targeted microbubbles have been used to image tumor associated 
angiogenesis using ultrasound (Willmann et al. 2010).  Finally, MRI contrast agents 
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targeted towards the folate receptor have been used for the molecular imaging of ovarian 
cancer (Konda et al. 2001).  Numerous other contrast agents have been targeted towards 
cancer-associated markers using these techniques.   
MRS has been investigated in combination with MRI for molecular imaging of 
cancer.  By defining a cancerous region of interest (ROI) with MRI, MRS has been 
successfully used to map the spatial distribution of many metabolites including total 
choline, which is elevated in cancer, providing the ability to evaluate cancer metabolism 
along with giving insight into intertumoral spatial heterogeneity (Horska and Barker 
2010).  In a separate study, the level of MR visible mobile lipids within tumors was 
shown to correlate with apoptosis and provided a measure of the efficacy of anti-cancer 
therapy (Liimatainen et al. 2008).  Though MRS is a promising tool for providing 
molecular and functional information, low sensitivity remains problematic. 
Positron emission tomography (PET) was one of the first imaging techniques to 
provide solely functional information on cancer.  By exploiting the Warburg effect, 
radiolabeled fluorodeoxyglucose (
18
F-FDG) is taken up to a higher degree in 
metabolically active cancers.  Coupled with CT, this technique has become a standard 
clinical tool for the evaluation of solid tumors and the measurement of tumor response to 
therapy (Kelloff et al. 2005).  
1.5 Optical Imaging  
Optical imaging has yet to see widespread adoption in clinical practice but has 
become the most widely used imaging technique in research settings.  This is possibly 
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due to the versatility of optical imaging agents, which can be engineered to provide 
highly specific information on various molecular targets (Weissleder and Pittet 2008).  
Optical imaging agents rely on the emission of photons within the visible-NIR range, 
either through bioluminescence or fluorescence to obtain molecular information.  
Bioluminescence imaging is most commonly used in systems engineered to 
express the luciferase protein.  When the luciferase substrate, luciferin, is added to the 
system, light is produced through an ATP and O2 dependent reaction (Wilson and 
Hastings 1998).  This reporter system has been used to measure the transcriptional 
regulation of various oncogenes, the activation of apoptosis, and the response of cancer 
associated genes to therapy (Gross and Piwnica-Worms 2005). Bioluminescence has been 
used as a tool for cellular analysis and an in vivo research tool.  In mice, cancer cells 
expressing luciferase are often used to 
monitor tumor growth with time and the 
effect of anti-cancer therapy on tumor size 
(Lim, Modi, and Kim 2009). 
Fluorescence imaging relies on the 
detection of endogenous or exogenous 
fluorophores following the input of 
excitation energy. Similarly to luciferase, 
fluorescent proteins have seen widespread 
research use for their ability to serve as 
Figure 1.3.  The Near Infrared (NIR) window.  
The NIR window (670-900 nm) is a region of the 
electromagnetic spectrum with minimal absorption 
from hemoglobin and water.  Fluorophores which 
emit within the NIR window have greater tissue 
penetration and detection sensitivity.  Reprinted by 
permission from Macmillan Publishers Ltd: Nature 
Biotechnology (Weissleder 2001), copyright (2001). 
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genetic reporters (Gross and Piwnica-Worms 2005).  Green fluorescent protein (GFP), 
which was the subject of the 2008 Nobel Prize in chemistry, was the first fluorescent 
protein to be designed.  Due to the wavelength of GFP, applications to in vivo imaging 
are limited due to the poor tissue penetration and scattering of green light.  For in vivo 
imaging, red shifted fluorescence between 650-900 nm is ideal (Weissleder 2001).  This 
NIR window has low absorbance from hemoglobin and water allowing for maximum 
penetration of light and increased signal detection (Figure 1.3). In addition, light 
scattering, the process of absorption and re-emission of light in the non-forward direction 
of travel, can result in signal loss (Ntziachristos 2010).  Similar to issues with light 
absorption, scattering is decreased at higher wavelengths, making the NIR window ideal 
for biological imaging.  The development of longer wavelength fluorescence proteins 
such as red fluorescent protein (RFP), near infrared fluorescent protein (NIRFP), and 
Infrared Protein (IFP) have since expanded their in vivo capabilities (Shcherbakova and 
Verkhusha 2013, Shu et al. 2009).   
Unlike genetic reporters, small molecule fluorophores are exogenous agents, 
which can be used to obtain functional information when added to cells or in vivo 
systems.  Reporter fluorophores can be categorized into three groups based on their 
mechanism of action: Nonspecific distributing agents, targeted agents, and activatable 
agents (Weissleder 2001).  Nonspecific distributing agents are free fluorophores, which 
distribute through tissue based on blood flow and perfusion.  They are not targeted and 
therefore are most useful for the measurement of vascular perturbations.  Three 
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fluorophores within this category, indocyanine green, fluorescein, and methylene blue 
have seen clinical adoption and are FDA approved for the evaluation of disease. 
 Indocyanine green (ICG) is a tricarbocyanine dye with fluorescence in the NIR 
region.  ICG has no functional groups, limiting its potential for conjugation to targeting 
moieties, however it is highly useful in the measurement of vascular blood flow 
(Marshall et al. 2010).  ICG is clinically approved for determining cardiac output, hepatic 
function and liver blood flow and for ophthalmic angiography (Nguyen and Tsien 2013).   
Fluorescein is a clinically approved dye with fluorescence emission at 520 nm.  
Because of this lower wavelength, fluorescein has poor tissue penetration, but can be 
used successfully for measuring vascular flow in the eye. Fluorescein is clinically 
approved for diagnostic angiography or angioscopy of the retina and iris vasculature 
(Nguyen and Tsien 2013).   
One method of improving fluorescence contrast is to conjugate fluorophores to 
targeting ligands.  Similar to molecular imaging techniques discussed for CT, ultrasound, 
and MRI, this allows for selective accumulation of signal in the vicinity of the target.  
Targeting fluorophores results in an improved signal to background as a function of time 
as non-bound fluorophore clears from circulation.   NIR targeted dyes have been used to 
image cancer signatures including folate receptor, EGFR, and HER2/Neu (Moon et al. 
2003, Ke et al. 2003, Terwisscha van Scheltinga et al. 2011).  In addition, probes have 
been designed targeted towards markers of apoptosis such as phosphatidylserine exposure 
on the outer leaflet of the cell membrane (Zhang and Zhao 2013). 
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 Though problems faced in absorption and scattering of light can be mitigated by 
imaging within the NIR window, issues with detection sensitivity remain.  In mouse 
models, fluorescence from alfalfa-containing chow can lead to high background signal in 
the digestive tract.  This fluorescence can be significantly decreased by feeding mice 
purified chow with inherently low fluorescence (Inoue et al. 2008).  The combination of 
this low fluorescence diet and NIR fluorescence has made optical imaging in mice a 
powerful research tool for the evaluation of cancer.  Despite this, translation of these 
techniques to humans remains challenging due to larger tissue depths.  Certain tissue is 
more amenable to optical imaging then others and must be taken into consideration when 
developing fluorescent imaging agents.  Breast tissue, due to its fatty composition and 
compressibility has been shown to allow up to 10 cm of penetration by NIR light 
(Weissleder 2001).   
1.6 Activatable Fluorescence 
Activatable fluorescence offers a number of advantages to both free and targeted 
fluorophores.  Targeted molecular imaging agents provide a measurement of target 
expression; however activatable agents can provide a measure of not only protein 
expression, but enzymatic activity as well.  In addition, the signal to noise of an 
activatable agent is not solely dependent on the rate of clearance but also upon the 
activity of the target.  Finally, in addition to providing a high degree of functional 
information, a single enzyme can cleave multiple substrate molecules, allowing for the 
amplification of a signal through increased accumulation of fluorescent product, 
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decreasing background signal, and thus increasing detection sensitivity (Rao, Dragulescu-
Andrasi, and Yao 2007).  
A commonly used research method of fluorescence activation is Föster (or 
Fluorescence) Resonance Energy Transfer (FRET).  FRET imaging exploits non radiative 
energy transfer between a donor fluorophore and an acceptor chromophore (which may 
also be fluorescent) in close spatial proximity (Jares-Erijman and Jovin 2003).  When two 
fluorophores are used, energy is transferred from a lower wavelength emission to a higher 
wavelength emission by intermediate absorption by the longer wavelength fluorophore.  
The intensity of the higher wavelength emission can be used as a measure for the degree 
of spatial interaction between the two fluorophores, since the strength of the interaction 
depends on the inverse sixth power of the interfluorophore distance.  FRET based 
technologies have been utilized extensively in research and have been used to image 
numerous biological processes including RAS signaling and calcium signaling related to 
cancer (Murakoshi et al. 2004, Mochizuki et al. 2001). 
Incorporation of non-fluorescent chromophores in FRET based imaging is 
referred to as ‘dark quenching’ (Jares-Erijman and Jovin 2003).  Because fluorescence is 
dissipated through vibrational relaxation of the dark quencher, the complex remains dark 
when in close proximity, and only becomes fluorescent upon separation of the 
fluorophore from the dark quencher.  One of the earliest activatable probes based on this 
design was developed for the detection of nucleic acids (Tyagi and Kramer 1996).  This 
probe consisted of single strand DNA with a target strand lying in the middle of two 
complementary arms which annealed in solution.  One arm was esterified to a 
21 
 
fluorophore, and the other to a complimentary dark quencher.  When annealed, the 
complex was non-fluorescent, however following hybridization of the middle target 
strand to a homologous strand of DNA, the fluorophore and quencher were separated 
resulting in fluorescence emission. 
A third mechanism of quenching useful for the development of activatable 
fluorophores is contact quenching.  When fluorophores are within a tight spatial 
proximity, they can undergo stacking and result in loss of fluorescence.  Recently, this 
quenching mechanism has been exploited for imaging of secreted phospholipase A2 
using the phospholipid conjugated fluorophore, 1-palmitoyl-2-(6-((7-nitro-2-1,3- 
benzoxadiazol-4-yl)amino)hexanoyl)-sn-glycero-3-phosphocholine (NBD-PC).  By 
incorporating NBD-PC into micelles at a high mole fraction, 90% quenching of 
fluorescence was achievable.  The addition of sPLA2 resulted in disruption of the 
micelles and a restoration of fluorescence (Gao et al. 2015).   
Several protease activatable fluorophores have been developed using both dark 
quenching and contact quenching.  One of the earliest designed involved a graft 
copolymer consisting of poly-L-lysine incorporating the fluorophore, Cy 5.5, quenched 
through contact quenching.  Cleavage of the polypeptide from lysosomal cysteine/serine 
proteases in tumors allowed for activation of fluorescence and imaging of cancer 
(Weissleder et al. 1999). Expanding from this design, a matrix metalloprotease (MMP) 
sensitive probe was developed conjugated to Cy 5.5 and specific to MMP-2 (Bremer, 
Tung, and Weissleder 2001).  Probes similar to these are commercially available under 
the trade names ProSense and MMPSense and have been used for research on the 
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detection of colorectal cancer, pancreatic cancer, and the investigation of breast cancer 
progression (von Burstin et al. 2008, Clapper et al. 2011, Baeten et al. 2009). 
Phospholipase specific probes have also been developed using dark quenching.  
By placing a fluorophore at the sn-2 position of a phospholipid and replacing the head 
group for a quencher, PLC selective activatable probes were generated and shown to be 
capable of imaging PLC in tumors (Mawn et al. 2011).  Similar probes were developed 
for specificity towards PLA2 by incorporating a 12-carbon spacer between the 
fluorophore and ester linkage at the sn-2 position (Popov et al. 2010).  In designing a 
cPLA2 activatable fluorophore, arachidonic acid at the sn-2 position is necessary since 
cPLA2 is the only phospholipase with absolute specificity for arachidonic acid at this 
position (Gijon and Leslie 1999). Furthermore, crystallographic analysis of 
cPLA2 identifies a small pocket where the phospholipid head group lies during lipolysis 
(Dessen et al. 1999). The presence of a large quencher at this position would most likely 
decrease activity due to steric hindrance.  
An alternate method for generating activatable fluorescence is to use chemical 
caging of fluorophores (Ellis-Davies 2007).  This technique avoids the need for a bulky 
quencher, which can often interfere with enzymatic activity.  In addition, this technique 
does not rely on spatial distances for quenching and therefore a higher percentage of 
quenched fluorescence can be achieved.  Chemical caging involves the esterification or 
amidification of resonant active hydroxyls or amides resulting in altered fluorescent 
properties.   
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Such probes have been designed with photo-labile groups, which become actively 
fluorescent only after light is introduced into the system (Warther et al. 2010).  β-
galactosidase sensitive probes have also been designed using this technique through 
conjugation with beta galactose (Tung et al. 2004, Kamiya et al. 2007).  Sulfatase 
sensitive probes have been developed through conjugation with sulfate (Beatty et al. 
2013).   Similarly activatable probes targeted towards reactive oxygen species through 
conjugation with aryloxyphenols have been developed (Setsukinai et al. 2003).  Finally, 
γ-glutamyl hydroxymethyl rhodamine green was developed and found to specifically 
activate in the presence of γ-glutamyltranspeptidase, which is overexpressed in various 
cancers (Urano et al. 2011). 
 A phospholipase activatable fluorophore was developed previously using caged 
fluorescence (Huang et al. 1994).  In this design, arachidonic acid was conjugated to 7-
hydroxycoumarin (7-HC) through esterification of the free hydroxyl.  It was shown that 
this probe could be activated in the presence of purified cPLA2.  Intriguingly, this 
activation was shown to occur at an identical rate to that of endogenous substrate 
implying that cPLA2 activity does not require an intact phospholipid with a glycerol 
backbone and phosphorylated head group. 
A major limitation to the design of 7-HC is the fluorescence emission of 7-HC, 
which occurs at a 460 nm maximum wavelength.  Probes within this region of visible 
light have significant absorption in biological tissue due to the presence of hemoglobin 
(Weissleder 2001).  For in vivo imaging, fluorescence within the NIR region (Figure 1.3) 
is ideal for limiting tissue absorption and allowing maximum penetration of light. 
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1.7 Near Infrared Fluorescence Guided Surgery 
Fluorescence guided surgery is a technique rapidly gaining attention within the 
scientific and medical communities.  Fluorophores which either accumulate in tumors or 
which activate specifically in tumors can provide a guide for surgeons and increase the 
efficacy of tumor resection, thereby minimizing the potential for tumor reoccurrence and 
metastasis (Nguyen and Tsien 2013).  The success of surgical resection is evaluated using 
histology by analyzing the surgical margins of the excised tissue (Singletary 2002).  
‘Positive margins’, the case where cancer cells lie at the cut edge, have been correlated 
with increased probability of recurrence and metastasis (Meric et al. 2003).  
Fluorophores, which accumulate in tumors are typically given intravenously and must be 
optimized with respect to dose and time in order to allow for systemic clearance thereby 
decreasing background and maximizing signal to noise (Nguyen and Tsien 2013).  
Activatable fluorophores allow for topical application during surgery, thereby eliminating 
the need for systemic administration.  This reduces the time necessary to obtain suitable 
contrast and reduces the amount of compound that is needed, which can minimize side 
effects.  In breast cancer specifically there is a great need for improved tumor resection as 
the positive surgical margin rates have been shown to range from 5-49% based on the 
study performed (Vahrmeijer et al. 2013). 
As previously discussed, ICG and fluorescein are both under investigation for 
their use as contrast agents in fluorescence guided surgery (Nguyen and Tsien 2013).  
Because both are FDA approved, they offer reduced challenges in designing off-label 
clinical trials.  ICG distributes diffusely and accumulates within tumors through the 
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presence of increased tumor vasculature (Marshall et al. 2010).  ICG, injected i.v., has 
been extensively investigated for its ability to aid the surgical resection of several 
carcinomas including skin, gastrointestinal, lung and breast (Schaafsma et al. 2011, Judy 
et al. 2015, Keating et al. 2016).  Adverse effects of systemic ICG administration have 
been observed including anaphylaxis (Hope-Ross et al. 1994).  Like ICG, fluorescein also 
distributes diffusely.  In a study using fluorescein for the guided resection of gliomas, 
patients with fluorescein administered i.v. had a higher rate of gross total tumor resection 
(Shinoda et al. 2003).  In addition patients who underwent gross total tumor resection had 
a significantly enhanced survival, giving further evidence for the value of complete tumor 
resection during surgery.  Unlike ICG, fluorescein does not fluoresce in the NIR.  
Therefore, high doses were needed for tumor visualization increasing the risk of off-
target effects, a potential limiting factor in future development.   
Efforts to improve fluorescein accumulation in cancer, and thus increase detection 
sensitivity, have been carried out through conjugation to folate resulting in targeted 
accumulation on the folate receptor, overexpressed in numerous cancers (van Dam et al. 
2011).  An in human study on the surgical use of folate conjugated fluorescein in ovarian 
cancer demonstrated its ability to enhance the detection of tumor deposits versus visual 
inspection.   
Antibody conjugation has also emerged as a viable means of targeting 
fluorophores to cancerous tissue for the aid of surgical resection.  In a study investigating 
the surgical resection of melanoma, bevacizumab, panitumumab, tocilizumab or non-
specific IgG were conjugated to an NIR fluorophore (IRDye800CW) and injected i.v. in 
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mice bearing melanoma tumor xenografts.  It was determined that all antibody 
conjugated dyes, with the exception of IgG control, were able to discern cancerous from 
healthy tissue (Day et al. 2013).   
5-aminolevulinic acid (5-ALA) is a precursor for porphyrin synthesis needed for 
the generation of hemoglobin.  5-ALA is non-fluorescent, but can be taken up by cancer 
cells and converted to fluorescent protoporphyrin IX as part of the synthesis of heme 
(Regula et al. 1995).  Unlike ICG and fluorescein, 5-ALA is a prodrug and not dependent 
to the same degree on disrupted vasculature.  5-ALA is under investigation for 
fluorescence guided surgery and has shown promise for its use in the surgical resection of 
gliomas.  In a phase III clinical study it was shown that the patient group which 
underwent 5-ALA guided surgery had a decreased percentage of repeat surgery and an 
increased 6-month progression free survival compared to the control cohort not treated 
with 5-ALA  (Stummer et al. 2006). 
The growth of activatable fluorophores can expand the capabilities of 
fluorescence guided surgery and decrease the reliance on vasculature fluorophore 
retention, which may vary between tumors.  In addition, probes are also required that can 
identify cancerous tissue at sites distal to the primary tumor which may have more 
normalized vasculature and not respond to perfusion based fluorophores.  Finally, agents 
that are selective to molecular characteristics of cancer can provide functional 
information while serving as a guide for resection. 
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1.8 Scope of Thesis 
This project aims to develop cPLA2 selective activatable red-shifted fluorophores 
for use in the exploration of cPLA2 activity in breast cancer and for their use as a contrast 
agent for NIR fluorescence guided surgery.  Our investigation began with the observation 
that 7-HC was hydrolyzed by purified cPLA2 despite the absence of a glycerol backbone 
and phosphorylated head group.  We therefore first set out to synthesize arachidonic acid 
esterified fluorophores, similar in structure to 7-HC, but employing fluorophores shifted 
closer to the NIR window.  We then evaluated the specificity of the developed probes to 
cPLA2 in breast cancer cell lines.  Finally, we assessed the activation of cPLA2-sensitive 
probes in vivo to gauge their potential as contrast agents for surgical resection. 
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Chapter 2: Materials and Methods 
2.1 Materials 
 Solvents for synthesis were purchased through Fisher Scientific.  Resorufin, 
resorufin sodium salt, naphthofluorescein, palmitoyl chloride, porcine pancreatic 
phospholipase A2, arachidonyl trifluoromethyl ketone, bromoenol lactone, ionomycin, 
and H2O2 30% (w/w) were purchased from Sigma-Aldrich. 7-Hydroxy-9H-(1,3-dichloro-
9,9-dimethylacridin-2- one (DDAO), arachidonoyl chloride, and LY311727 were 
purchased from Santa Cruz Biotechnology. 7-HC was purchased from Cayman Chemical. 
Syto 9 was purchased from Life Technologies. HOESCHT 333258 was generously 
provided by the Cellular and Molecular Imaging Core Facility (CMIC) at the Norwegian 
University of Science and Technology (NTNU).  Egg phosphatidylcholine was purchased 
from Avanti Polar Lipids.   AVX-235 was provided by Dr. Berit Johansen from Avexxin 
Pharmaceuticals (Trondheim Norway). MDA-MB-231, SKBR3, and MCF-7 cell lines 
were purchased from the American Type Culture Collection (ATCC). 4175-Luc+
 
cell 
line, a lung metastatic derivative of the MDA-MB-231 cell line was generously provided 
by Dr. Andy Minn (Minn et al. 2005).  Human cPLA2 rabbit monoclonal antibody and 
human β-tubulin rabbit monoclonal antibody were purchased through Cell Signaling 
Technology. IRDye
®
 800 conjugated goat anti-rabbit IgG was purchased through LI-
COR Biosciences.  Athymic NCR nu/nu 01B7 female mice were purchased through 
Charles River, Production.  cPLA2 CRISPR/Cas9 KO Plasmid, control CRISPR/Cas9 
plasmid, UltraCruz
®
 transfection reagent and plasmid transfection media were purchased 
through Santa Cruz Biotechnology. 
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2.2 Flash Column Chromatography 
 A 1000 mL stopcock separation column was dried overnight under air flow. 
Approximately 1/3 of the column was loaded with silica gel suspended in hexanes.  The 
walls of the column were rinsed evenly with hexanes to transfer all silica gel to the 
bottom.  The column was packed with a hexanes mobile phase under pressurized air.  A 
small layer of sand was added onto the silica gel to protect from physical perturbation.  
The sample was dissolved in the smallest possible volume of hexanes and separated 
under pressurized air according the procedures described. 
2.3
 1
H NMR Spectroscopy 
Samples were dried through rotary evaporation and lyophilized overnight to 
remove residual solvents.  Samples were dissolved in the appropriate deuterated solvent 
based on solubility and spectra obtained on a 360 MHz Bruker Avance DMX  
spectrometer with gradient capabilities running the Topspin software package.  
Shimming was adjusted through optimization of the lock signal by adjustment of x, y, 
and z gradients without spinning, then adjustment of z and z
2
 gradients with spinning at 
20 Hz.  Spectra were acquired using a zg30 pulse sequence (NS= 16, SW = 20.6 ppm). 
The spectra were analyzed with MestReNova software.  First and second order phases 
were adjusted relative to the highest intensity peak and baseline was adjusted using a 
Whitaker baseline correction. Signals were referenced to the solvent peak. 
2.4 Mass Spectrometry  
Matrix-assisted laser desorption / ionization time of flight (MALDI-TOF) was 
performed on a Bruker MALDI-TOF. Samples were prepared in saturated solutions of 
either 2-(4′-hydroxybenzeneazo)benzoic acid or α- cyano-4-hydroxycinnamic acid as a 
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50:50 mixture (acetonitrile/ H2O) with 0.1% trifluoroacetic acid.  1 µL of each sample 
was placed on an MTP AnchorChip TM 600/384 TF MALDI target (BrukerDaltonik).  
The mixture was dried at room temperature to allow for matrix crystallization.  Spectra 
were generated using an Autoflex III smartbeam 1 MALDI-TOF-MS mass spectrometer 
(BrukerDaltonik) operating in the linear and reflectron positive ion mode.  A smartbeam 
laser (200 Hz) was used to irradiate matrix and generate ions.  Electrospray ionization 
(ESI) mass spectrometry was performed with a Single Quadrapole (SQ) Detector 
(Waters) coupled with Ultra Pure Liquid Chromatography (Acquity). Samples were 
dissolved in ethanol and passed through a gradient (80 - 20%) of acetonitrile in water. 
Results were analyzed using MestReNova for the presence of ions with predicted product 
mass. 
2.5 Liposomal Preparation 
Probe and egg phosphatidylcholine were mixed together in a 25 mL round bottom 
flask in chloroform at a mole fraction of 0.05-0.1.  The solvent was removed under a 
slow stream of nitrogen gas.  The resulting lipid cake was resuspended in aqueous buffer 
followed by sonication in a 4 °C water bath sonicator until an optically clear solution was 
obtained, typically 10-15 minutes.  Buffer was added to result in a concentration of 100 
µM probe for in vitro and 400 µM probe for in vivo analysis.  Liposomes were used 
immediately following formation. 
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2.6 In Vitro sPLA2 Assay 
 In a 96 well plate, 80 μL of 50 mM Tris (pH 7.4) with 1.1 mM CaCl2 was mixed 
with 0−100 units of sPLA2 Group IB (Sigma) in the presence or absence of 100 μM 
LY311727 (Santa Cruz Biotech) in DMSO resulting in a total volume of 90 μL per well. 
To initiate the reaction, 10 μL of liposomes containing activatable probe was added to 
each well, and fluorescence was measured as a function of time on a Spectra Max M5 
fluorescent plate reader (top read; ex/em, 600/660 nm for DDAO, 595/660 nm for 
naphthofluorescein, and 572/585 nm for resorufin). 
 
2.7 Cell Culture 
 All cell lines were maintained in Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (HyClone Laboratories), 1% L-glutamine 
(Mediatech), and 1% penicillin−streptomycin (Mediatech). 4175-Luc+ cells were 
additionally maintained with 5 µg/mL blasticidin (Invitrogen).  Frozen cells (1-2 x 10
6
 
cells per vial) were brought up through a rapid thaw at 37ºC and immediately placed in 
10 mL of 37 °C media.  DMSO containing freezing media was removed through 
centrifugation (1000 rpm, 4 °C, 4 min) and cell pellet was resuspended in 8 mL of media 
at 37 °C.  Cells were expanded and maintained at 37 °C, 5% CO2, in a humidified 
environment.  Cells were tested immediately upon receipt and bi-annually thereafter for 
mycoplasma.   
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 Cells were passaged routinely through washing 2x with 4 °C Phosphate Buffered 
Saline (PBS) followed by detachment from the tissue culture flask through addition of 
Trypsin-EDTA (0.25%) (Thermo Fisher Scientific).  Following detachment, the protease 
was neutralized through addition of fresh 37 °C media with serum. Cells were split at a 
1:10 ratio, and used for up to 20 passages before being discarded.  Cells were counted on 
a Neubauer hemocytometer following centrifugation at 1000 rpm, resuspention in PBS 
and dilution (1:1) with Trypan Blue to stain for non-viable cells. 
2.8 Cellular Fluorescence Activation Assay 
 Cells were seeded at 1.5-3.5 x 10
4
 cells in a 96-well black-wall, clear-bottom plate 
24 hours prior to experiment.  The medium was aspirated, and cells were washed 1× in 
0.1 mL of PBS (4°C, without Ca
2+
 and Mg
2+), and 90 μL of phenol red free DMEM 
containing drug treatments or vehicle control was added to each well.  For phospholipase 
inhibition experiments, 10 µM inhibitor was incubated with cells for 4 hours (2.5 hours 
for AVX-235).  Assays were initiated by adding 10µL of liposomes containing DDAO 
fluorescent probes to the wells.  Fluorescence was monitored as a function of time on a 
Spectra Max M5 fluorescent plate reader at 37°C (bottom read, ex/em 600/660 nm).  For 
AVX-235 inhibition and cellular comparison studies, fluorescence was monitored as a 
function of time on a LI-COR Odyssey
®
 CLx Imaging System (700 nm channel, ex/em: 
685/720). 
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2.9 Fluorescence Microscopy 
Wide Field Fluorescence Microscopy 
 4175-Luc+ cells were seeded at 2.5 × 10
5
 cells/mL in 0.5 mL and cultured 
overnight in a 24-well plate. The media was aspirated, and the cells were washed 2× in 
PBS. Phenol red free DMEM (450 μL) with 1 μM Syto 9 (Invitrogen) was added to each 
well 3 h prior to analysis. Liposomes were added either 30 minutes or 3 h prior to 
analysis. Immediately before analysis, DMEM was aspirated, cells were washed 1× in 
PBS, and fresh phenol red free DMEM was added. For live cell time course microscopy, 
the probe was added immediately prior to analysis, the plate was loaded into a 5% CO2, 
37 °C chamber and allowed to equilibrate for 30 minutes.  Wide field fluorescence 
microscopy was performed on an EVOS FL Auto Cell Imaging System (Life 
Technologies). An LED light cube for Cy5 was used to excite DDAO fluorescence, and a 
GFP light cube was used to excite Syto9 fluorescence. Images were acquired at 40× 
magnification and analyzed with ImageJ. 
Confocal Fluorescence Microscopy 
 Cells were seeded at 1.5-3.5 x 10
4
 cells in a 96 well black-wall, clear bottom plate 
24 hours prior to experiment.  The medium was aspirated, and cells were washed 1× in 
0.1 mL of PBS (4 °C, without Ca
2+
 and Mg
2+), and 90 μL of phenol red free DMEM 
containing drug treatments or vehicle control was added to each well.  For phospholipase 
inhibition experiments, 10 µM AVX-235 or vehicle control was added and cells were 
incubated for 1.5 hours.  10 μL of probe containing liposomes in PBS was added and the 
34 
 
plate was incubated for 2.5 hours at 37 °C.  The medium was removed and 100 μL of 
phenol red and FBS free media (37 °C) was added.  1 µL of HOESCHT 333258 nuclear 
stain was added.  Confocal fluorescence microscopy was performed on a Leica SP8 
imaging system and analyzed with Image J. 
2.10 In Vivo Mouse Models 
Anesthesia 
 Isoflurane was administered to achieve anesthesia.  In a clean induction chamber, 
1-5 mice were simultaneously induced with 1 L/min O2 containing 4% isoflurane.  
Induction was assessed through loss of movement, slowed rate of breathing, and an 
absence to response of a toe pinch.  Anesthetized mice were maintained at 1 L/min O2 
containing 2% isoflurane.   
Euthanization 
Mice in a cage without a filtered lid were placed in a clean CO2 chamber and 
sealed.  CO2 was injected at a fill rate of 10-30% chamber volume displacement per 
minute for 10 minutes.  Mice were monitored continuously during the procedure and 
assessed for lack of movement.  Euthanization was confirmed through cervical 
dislocation. 
Tumor Inoculation 
 Cells were expanded in T-150 tissue culture flasks to ~80% confluency.  Cells 
were detached through trypsinization, washed 2x in 4 °C PBS, and adjusted to 2 x 10
6
 
cells / 100 µL of PBS.  The suspension was diluted 1:1 with 4 °C Matrigel
®
 (Corning) 
and placed in a 6-well plate on ice.  Prior to injection, cells were resuspended and drawn 
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up into a 1 mL syringe with a 27-gauge needle.  Air bubbles were removed through 
gentle tapping. The syringe was depressed until a stream of cell media was ejected 
consistently without air.  The area of injection was sterilized with 70% isopropanol.  For 
tumor xenograft inoculation, the cells were injected subcutaneously in the right or left 
lower flank or superior shoulder flank.  For orthotopic inoculation, cells were injected 
into the mammary fat pad inferior to the lower nipple of the mouse.  The mammary fat 
pad was located by gently pinching the skin and held in place for inoculation. Following 
injection, sterile gauze was used to aid in clotting.  Mice were monitored the day 
following inoculation and every three days thereafter in order to assess tumor growth and 
to evaluate general health.  
Probe Injections 
 For intravenous (i.v.) injection, mice were anesthetized as previously described.  
The tail vein was dilated through immersion of the tail in 37 °C water.  Prior to injection, 
the compound was drawn up into a 1 mL syringe with a 30-gauge needle.  Air bubbles 
were removed through gentle tapping. The syringe was depressed until a stream of fluid 
was ejected consistently without air.  The tail was sterilized with 70% isopropanol.  
Following application of tension to the tail, the needle was inserted level with the vein.  
 For intraperitoneal (i.p.) injections, mice were used either with or without 
anesthesia.  Prior to injection, compound was drawn up into a 1 mL syringe with a 30-
gauge needle and treated as before.  The area of injection was sterilized with 70% 
isopropanol.  Injection was done in the right or left lower abdominal quadrant in order to 
avoid the anterior liver and bladder in the midline.   
 
36 
 
2.11 Optical Imaging 
IVIS Spectrum 
 Fluorescence was acquired on a PerkinElmer IVIS Spectrum using a 640 nm 
excitation filter and a 680 nm emission filter (Bin: (M)8, FOV: 22.3 cm
2
, f2, 3s 
exposure).  For spectral unmixing, two excitation filters in combination with emission 
filters were used (570 nm excitation with emission 620-780 nm in 20 nm intervals and 
640 nm excitation with emission 680-780 nm in 20 nm intervals).  Images were 
processed and quantitated in LivingImage 4.4.  ROIs were defined with circular shape 
tools.  Fluorescence is reported, unless otherwise noted, as Average Radiant Efficiency, 
measured in photons per second and corrected for the area of the ROI and the light source 
efficiency at the acquired sample distance and filter settings ([p/sec/cm
2
/sr]/[µW/cm
2
]). 
LI-COR Pearl Impulse 
 Fluorescence was acquired on a LI-COR Pearl Impulse scanner using the 700 nm 
fluorescence channel (ex/em: 685/720 nm).  Images were processed and quantified in 
Image Studio Lite.  ROIs were defined by tracing the tissue in white light mode.  
Fluorescence is quantified as relative fluorescence units, unless otherwise noted.   
2.12 Ex Vivo Tumor Imaging 
 48 hours after injection of 40 nmol probe, mice were euthanized according to the 
previously described protocol. Tumor and organs were resected, washed in PBS, and 
weighed.  Tissue was placed in a 24 well plate.  Fluorescence was acquired (ex/em: 
640/680 nm).  ROIs were defined and quantified in LivingImage. 
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2.13 Ex Vivo Tumor Painting 
 Untreated mice bearing orthotopic or xenograft tumors were euthanized according 
to the previously described protocol and tissue was resected.  Tissue was washed in PBS 
and sliced evenly using a razor into approximately 1 mm sections, which were weighed.  
The sections were placed in DMEM with serum and cultured for two hours at 37 °C, 5% 
CO2.  The medium was replaced with phenol red and serum free media (37 °C) prior to 
the addition of probe. Liposomes (100 µL containing 20 nmol probe at MF 0.05) were 
pipetted evenly on top of the tissue.  For analysis, the plate was transferred to either the 
IVIS Spectrum or LI-COR Pearl Impulse imaging systems.  Fluorescence was acquired at 
ex/em: 640/680 or 700 nm channel, respectively for each imaging system.  Fluorescence 
emission was quantified with LivingImage or Image Studio Lite, respectively. 
2.14 Protein Immunoblot 
 Cells were plated in 10 cm dishes at 2.5 × 10
5
 cell/mL in 12 mL of medium 24 
hours prior to the experiment.  Following washing 2× with 4 °C PBS, cells were scraped 
on ice in radioimmunoprecipitation assay buffer containing cOmplete, mini EDTA-free 
protease inhibitor cocktail (Roche). Samples were vortexted and subjected to three cycles 
of freeze-thaw consisting of rapid freezing in liquid N2 followed by quick thaw at 37 °C 
using a dry block heater.  Cells were sonicated in a 4 °C water bath sonicator for 5 
minutes and placed on ice for 15 minutes.  Cell debris following lysis was pelleted by 
centrifugation (13,000 rpm for 10 min).  The supernatant was removed and protein 
concentration was quantified using the bicinchonic acid (BCA) protein assay kit (Pierce).  
Samples were adjusted to equal concentrations of protein, diluted 1:1 in Laemmli loading 
buffer (5% 2-mercaptoethanol), and heated to 95 °C for 5 minutes.  30 μL of 
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approximately 25 μg protein per well was resolved on a 10% SDS-PAGE gel and 
transferred to a 0.45 µm pore nitrocellulose membrane (Invitrogen).  The membrane was 
blocked in Odyssey blocking buffer (PBS) (LI-COR Biosciences) and blotted using 
primary antibodies for cPLA2 or β-tubulin (Cell Signaling).  The membrane was imaged 
through incubation with secondary antibody (goat anti-rabbit) conjugated to IRDye
®
 
800CW (LI-COR) and visualized using the LI-COR Odyssey
®
 CLx Imaging System.  
Bands were quantified with Image Studio Lite. 
2.15 CRISPR Gene Knockout 
 4175-Luc+ cells were seeded in 6 well plates at 1.5 x 10
5
 cells in 3 mL of 
antibiotic-free DMEM and cultured for 24 hours.  2 µg of plasmid DNA was diluted in 
150 µL Plasmid Transfection Media.  Diluted plasma DNA was added dropwise to 150 
µL of Plasmid Transfection Media containing 10 µL of UltraCruz® Transfection Reagent.  
The sample was vortexed and left to sit for 20 minutes at room temperature.  Prior to 
transfection, cells were replaced with 3 mL of fresh antibiotic-free DMEM.  Dropwise,  
plasma DNA solution was added to the well with gentle swirling.  Cells were incubated 
for 72 hours without a media change. 
 Cells were separated based on GFP expression using Fluorescence-Activated Cell 
Sorting (FACS) on a BD FACSJAZZ.  A non-transfected control was used to define a 
fluorescence cut-off prior to separation.  Cells were expanded in T25 flasks and used for 
up to 5 passages before being discarded. 
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2.15 Statistical Analysis 
 All data are reported as mean ± standard deviation, unless otherwise noted.  Data 
are listed as an average of three experimental results (n = 3), unless otherwise noted.  
Statistical probability (P) values were calculated using Microsoft Excel utilizing a two-
tailed Students t-test.  P values <0.05 were considered to be statistically significant. 
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Chapter 3: Chemical Synthesis 
3.1 Introduction 
 This Chapter describes the synthesis of a series of activatable constructs that 
release caged fluorescence when hydrolyzed by phospholipases. A cPLA2-activatable 
fluorophore probe had previously been described with caged fluorescence by 
esterification of arachidonic acid to the resonant active hydroxyl moiety present in 7-
hydroxycoumarin (7-HC) (Huang et al. 1994).  Though promising, the low wavelength 
emission of this fluorophore (460 nm) limits its in vivo capabilities.  Fluorophores within 
the NIR region of the electromagnetic spectrum (650-900 nm) have minimum absorbance 
from hemoglobin and water allowing for maximum penetration of light (Weissleder 
2001).  Therefore, we aimed to improve the design of 7-HC arachidonate using red-
shifted fluorophores that emit close to or within the NIR window.  
 The fluorophores were selected based on several properties that would enhance 
detection and increase specificity.  The fluorophore must possess a resonant active 
hydroxyl that can be esterified to result in masked fluorescence.  Furthermore, the 
wavelength of emission should lie in the NIR window to allow for maximum tissue 
penetration.  Finally, the fluorophore size must be small enough to allow cleavage by 
cPLA2.  Crystallographic analysis of cPLA2 has identified a small pocket where the 
phospholipid head group lies during lipolysis, therefore large fluorophores would likely 
result in steric hindrance, preventing cPLA2 mediated cleavage (Dessen et al. 1999).  
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Based on these considerations, three fluorophores were chosen as potential cPLA2 
imaging agents (Table 3.1).  
Resorufin (ex/em: 572/585 nm) is a small tricyclic fluorophore with one available 
hydroxyl group. Resorufin has been shown to have ablated fluorescence upon 
conjugation to a photoremovable protecting group (Theriot and Mitchison 1991). 
Naphthofluorescein (ex/em: 595/660 nm) contains two resonant active hydroxyl groups 
and has been shown to have reduced fluorescence upon conjugation (Sarpara et al. 1999).  
These two hydroxyls are available for esterification, allowing for the synthesis of a 
diarachidonate probe. 7-Hydroxy-9H-(1,3-dichloro-9,9-dimethylacridin-2-one) (DDAO) 
Table 3.1. Fluorophores used for fatty acid conjugation.  Resorufin, naphthofluorescein, and DDAO 
were conjugated to fatty acid(s) through esterification of their free hydroxyl group(s). 
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(ex/em: 600/660 nm) is an ortho-dichlorinated carbon analog of resorufin that results in 
redshifted fluorescence. DDAO has also been conjugated to form activatable 
fluorophores through conjugation of its hydroxyl group resulting in photoactivatable and 
sulfatase activatable probes (Beatty et al. 2013, Warther et al. 2010).  In order to 
synthesize cPLA2 selective activatable probes, free fluorophore was conjugated to 
arachidonic acid.  Control probes were synthesized through conjugation with palmitic 
acid, not expected to be cleavable by cPLA2. 
3.2 Naphthofluorescein Diarachidonate 
Naphthofluorescein (0.0775 mmol, 33.5 mg) was dissolved in 30 mL of pyridine 
at room temperature. Arachidonoyl chloride (0.31 mmol, 100 mg) was added to the 
solution. The flask was flushed with argon and left to stir at room temperature for 24 h. 
Pyridine was removed through rotary evaporation, and the resulting solid was dissolved 
in hexanes and filtered through a porous cotton plug to remove pyridinium salts. The 
solution was purified with flash column chromatography (silica gel, under N2) in 25 mL 
gradients beginning with ethyl acetate/dichloromethane (DCM) (2:8, v/v), followed by 
ethyl acetate/DCM (7:3, v/v), ethyl acetate (pure), and methanol/ethyl acetate (3:7, v/v). 
The product was isolated as a dark solid (76.4 mg, 98% yield). 
1
H NMR (360 MHz, 
CDCl3, δ ppm) 8.51 (d, 2H, J = 9.0 Hz, -CH- (Ar)) 7.97 (m, 1H, -CH- (Ar)) 7.55 (m, 2H, 
-CH- (Ar)) 7.22 (dd, 4H, J = 9.0, 2.63 Hz, -CH- (Ar)), 7.05 (d, 3H, J = 2.4 Hz, -CH- 
(Ar)), 6.60 (d, 2H, J = 8.8 Hz, -CH- (Ar)) 5.25 (m, 16H, -CH=), 2.70 (m, 12H, =CH-CH2-
CH=), 2.20 (t, 4H, J = 8.0 Hz, -CH2C(O)), 1.97 (m, 8H, -CH2-CH2-CH2C(O)), 1.58 
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(quintet, 4H, J = 7.2 Hz, Bu-CH2-CH=), 1.19 (m, 12H, CH3-CH2-CH2-CH2-), 0.77 (t, 6H, 
J = 6.7 Hz, CH3-). EI-MS (m/z): 1004.51 (M)
+
. 
3.3 Resorufin Arachidonate 
Resorufin (0.0775 mmol, 16.5 mg) was dissolved in 50 mL of pyridine and slightly 
cooled with liquid N2. Resorufin was not completely soluble in solution. Arachidonoyl 
chloride (0.31 mmol, 100 mg) was added to the solution. The flask was flushed with 
argon and left to stir at room temperature for 24 h. Following the reaction, the solution 
was clear with no solids present. Pyridine was removed through rotary evaporation, and 
the solid was dissolved in hexanes/DCM (1:1, v/v) and filtered through a porous cotton 
plug to remove pyridinium salts. The solution was purified with flash column 
chromatography (silica gel, under N2) in 25 mL gradients beginning with hexanes/DCM 
(1:1, v/v), followed by hexanes/DCM (9:1, 8:2, 7:3, 6:4, 1:1, 3:7, 1:9, v/v), DCM (pure), 
and DCM/ethyl acetate (19:1, v/v). The product was isolated as a yellow solid (7.7 mg, 
19.9% yield). 
1
H NMR (360 MHz, CDCl3, δ ppm) 7.80 (d, 1H, J = 8.7 Hz, -CH- (Ar)), 
7.44 (d, 1H, J = 7.4 Hz, -CH- (Ar)), 7.15 (d, 1H, J = 2.2 Hz, -CH- (Ar)) 7.12 (dd, 1H, J = 
8.6, 2.5 Hz, -CH- (Ar)), 6.86 (dd, 1H, J = 9.8, 2.0 Hz, -CH- (Ar)), 6.33 (d, 1H, 2.0 Hz,     
-CH- (Ar)), 5.38 (m, 8H, -CH=), 2.83 (m, 6H, =CH-CH2-CH=), 2.62 (t, 1H, J = 7.5 Hz, 
pro-RS-stereogenic -CHHC(O)) 2.37 (t, 1H, J = 7.5 Hz, pro-RS-stereogenic -CHHC(O)), 
2.23 (q, 2H, J = 7.2 Hz, -CH2-CH2-CH2C(O)) 2.14 (q, 2H, J = 7.2 Hz, Bu-CH2-CH=), 
1.86 (quintet, 1H, J = 7.5 Hz, pro-RS-stereogenic -CH2-CHH-CH2C(O)) 1.73 (quintet, 
1H, J = 7.5 Hz, pro-RS-stereogenic -CH2-CHH-CH2C(O)) 1.30 (m, 6H, CH3-CH2-CH2-
CH2-), 0.89 (t, 3H, J = 6.9 Hz, CH3-). EI-MS (m/z): 500.45 (M + 1)
+
.  
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3.4 DDAO Arachidonate 
DDAO (0.0325 mmol, 10 mg) was dissolved in 50 mL of pyridine. Arachidonoyl 
chloride (0.065 mmol, 27 μL) was added to the solution, and the reaction was carried out 
as described above. The solid product was dissolved in hexanes/DCM (1:1, v/v), filtered, 
and purified with flash column chromatography using 25 mL gradients of hexanes/ DCM 
(3:7, 2:8,1:9, v/v), DCM (pure), and DCM/ethyl acetate (19:1, 17:3, 7:3, 4:6, and 2:8, 
v/v). The product was isolated as a yellow solid (12.9 mg, 65% yield). 
1
H NMR (360 
MHz, CDCl3, δ ppm) 7.64 (d, 1H, J = 8.6 Hz, -CH- (Ar)), 7.62 (s, 1H, -CH- (Ar)), 7.21 
(d, 1H, J = 2.4 Hz, -CH- (Ar)), 7.11 (dd, 1H, J = 8.6, 2.4 Hz, -CH- (Ar)), 5.37 (m, 8H, -
CH=), 2.81 (m, 6H, =CH-CH2-CH=), 2.59 (t, 2H, J = 7.5 Hz, -CH2C(O)), 2.21 (q, 2H, J = 
7.2 Hz, -CH2-CH2-CH2C(O)), 2.03 (q, 2H, J = 6.8 Hz, Bu-CH2-CH=), 1.86 (s, 6H, 
C(CH3)2), 1.27 (m, 8H, CH3-CH2-CH2-CH2- and -CH2-CH2C(O), 0.87 (t, 3H, J = 7.2 Hz, 
-CH2-CH3). MALDI-TOF-MS (m/z): 593.94 (M)
+
. 
3.5 DDAO Palmitate  
DDAO (0.0325 mmol, 10 mg) was dissolved in 50 mL of pyridine. Palmitoyl 
chloride (0.065 mmol, 20 μL) was added to the solution. The reaction proceeded as 
described above, and the resulting solid was dissolved in hexanes/DCM (1:1, v/v), 
filtered, and purified with flash column chromatography using 25 mL gradients of DCM 
(pure) and DCM/ethyl acetate (19:1, 9:1, 8:2, and 1:1, v/v). The product was isolated as a 
yellow solid (5.9 mg, 33% yield). 
1
H NMR (360 MHz, CDCl3, δ ppm) 7.65 (d, 1H, J = 
8.5 Hz, -CH- (Ar)), 7.62 (s, 1H, -CH- (Ar)), 7.21 (d, 1H, J = 2.4 Hz, -CH- (Ar)), 7.11 (dd, 
1H, J = 8.6, 2.4 Hz, -CH- (Ar)), 2.57 (t, 2H, J = 7.6 Hz, -CH2C(O)), 1.86 (s, 6H, 
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C(CH3)2), 1.75 (quintet, 2H, J = 7.5 Hz, -CH2-CH2C(O)), 1.24 (m, 24H, CH3-CH2-CH2-
CH2-CH2-CH2-CH2-), 0.86 (t, 3H, J = 6.9 Hz, -CH2-CH3). MALDI-TOF-MS (m/z): 
567.24 (M
 
+ 1 + Na)
+
. 
3.6 Resorufin Palmitate 
Resorufin sodium salt (0.0774 mmol, 18.2 mg) was dissolved in 80 mL of 
pyridine and slightly cooled with liquid N2. Palmitoyl chloride (0.31 mmol, 95 μL) was 
added to the solution. The reaction proceeded as described above, and the resulting solid 
was dissolved in hexanes, filtered, and purified with flash column chromatography using 
25 mL gradients of hexanes/DCM (9:1, 8:2, 6:4, 2:8, v/v), DCM (pure), DCM/ethyl 
acetate (9:1, v/v), and ethyl acetate (pure). The product was isolated as a yellow solid (5.0 
mg, 14.3%). 
1
H NMR (360 MHz, CDCl3, δ ppm) 7.80 (d, 1H, J = 8.8 Hz, -CH- (Ar)), 
7.43 (d, 1H, J = 10.1 Hz, -CH- (Ar)), 7.15 (d, 1H, J = 2.2 Hz, -CH- (Ar)), 7.12 (dd, 1H, J 
= 8.6, 2.5 Hz, -CH- (Ar)), 6.86 (dd, 1H, J = 9.8, 2.0 Hz, -CH- (Ar)), 6.33 (d, 1H, J = 1.8 
Hz, -CH- (Ar)), 2.60 (t, 2H, J = 7.6 Hz, -CH2C(O)), 1.77 (quintet, 2H, J = 7.7 Hz, -CH2-
CH2C(O), 1.26 (m, 24H, CH3-CH2-CH2-CH2-CH2-CH2-CH2-), 0.88 (t, 3H, J = 7.0 Hz, 
CH3-). EI-MS (m/z): 452.21 (M
 
+ 1)
+
. 
3.7 Results 
For all probes, free fluorophore was conjugated to a fatty acyl chloride through a 
one-step reaction in pyridine (Figure 3.1).  Free fluorophore in pyridine existed as a dark 
red solution.  Following conjugation to a fatty acid, a change in solution color to yellow 
was observed (Figure 3.2).  This color change allowed for the visual monitoring of 
reaction progress.  Color change occurred rapidly (within seconds) when a sufficient 
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amount of excess fatty acyl chloride was added to the stirring solution.  The molar 
equivalents of fatty acyl chloride required to achieve a rapid color change varied for each 
given reaction.  Naphthofluorescein diarachidonate, resorufin arachidonate, and resorufin 
palmitate required 4 equivalents of fatty acyl chloride.  DDAO arachidonate and DDAO 
Figure 3.1. Scheme for probe synthesis.  Free fluorophore was coupled with a fatty acyl chloride 
through a one-step reaction in pyridine.  Arachidonoyl chloride was used to generate cPLA2 selective 
fluorophores.  Palmitoyl chloride was used to generate control probes. 
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palmitate required 2 equivalents of 
fatty acyl chloride.   
Column chromatography was 
monitored visually with product 
appearing as a colored band ranging 
from yellow to orange for resorufin 
and DDAO (Figure 3.3A).  
Napthofluorescein diarachidonate 
appeared as a dark purple band.  In 
addition, excitation with U.V. light (ex 312 nm) resulted in fluorescence of the product, 
which could be used to monitor the product’s mobility on a silica gel column when 
visualized in a darkened room using a U.V. lamp (Figure 3.3B).   For all probes, the 
product was eluted in early fractions of hexanes / ethyl acetate with slight variations 
between syntheses.   
Naphthofluorescein displays a maximum absorbance peak at 600 nm.  This 
absorbance was lost in naphthofluorescein diarachidonate.  Addition of 200 µL 1M 
NaOH to naphthofluorescein diarachidonate in egg phosphatidylcholine liposomes (MF 
0.1) to induce hydrolysis of the ester bond resulted in rapid (<1 min) restoration of the 
600 nm absorbance peak at room temperature.  Excitation at this wavelength resulted in 
fluorescence generation with a maximum of 660 nm.  The potential for quenching of 
naphthofluorescein diarachidonate was determined by measuring the difference in 
fluorescence (ex 600, em 660) of the ionized fluorophore at pH 9 (fluorescent) versus the 
Figure 3.2.  Naphthofluorescein palmitate reaction 
progress.  A)  Naphthofluorescein dissolved in 
pyridine resulted in a dark red solution.  B)   Addition 
of palmitoyl chloride resulted in a change to light 
yellow indicating successful conjugation.  
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protonated fluorophore at pH 3 (non fluorescent).  This change to acidic pH reduced 
naphthofluorescein diarachidonate fluorescence by 99.4%. 
 Conjugation of resorufin to both arachidonic acid and palmitic acid resulted in a 
shift of the 572 nm resorufin absorbance peak to 450 nm.  Addition of NaOH to induce 
hydrolysis of the ester bond resulted in a restoration of the 572 nm peak and a loss of the 
450 nm peak.  Excitation of resorufin at this wavelength resulted in fluorescence 
generation with a maximum of 585 nm.  The potential percentage for quenching was 
determined by analyzing the difference in 
fluorescence (ex 600, em 660) of the 
ionized fluorophore at pH 9 versus the 
protonated fluorophore at pH 3.  This was 
determined to be 99.8%. 
 DDAO contains a broad absorbance 
peak between 600 and 650 nm.  Similar to 
what was observed for resorufin, 
conjugation to either arachidonic acid or 
palmitic acid resulted in a shift in 
absorbance resulting in a broad peak 
between 400 and 450 nm.  In order to 
demonstrate the mechanism of activation 
for this compound, 100 Units of secreted 
phospholipase A2 (Group IB) was added to 
Figure 3.3.  Flash column chromatography of 
DDAO arachidonate.  A)  Product can be seen as 
a yellow band migrating in the center of the 
column.  B) Under U.V. light (ex 360 nm) the 
product fluoresces, aiding in separation from non-
fluorescent compounds. 
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egg phosphatidylcholine liposomes containing DDAO arachidonate (MF 0.1) and the 
change in absorbance and fluorescence spectra was recorded after 4 hours of incubation 
at 37°C in 50 mM Tris supplemented with 1.1 mM CaCl2.  It was observed that following 
incubation, a restoration of the 600-650 absorbance peak occurred which was 
accompanied by a restoration of fluorescence when excited at 600 nm (Figure 3.4).  
Determination of the theoretical quenching was performed through comparison of the 
fluorescence (ex 600, em 660) of the ionized fluorophore at pH 9 versus the protonated 
fluorophore at pH 3 and resulted in a 98.6% quenching of fluorescence. 
 
Figure 3.4. Mechanism of activation shown for DDAO arachidonate.  Absorbance in the esterified 
quenched state is shown in solid blue.  Absorbance in the unesterified state is shown in red.  Cleavage of 
the esterified probe (10 µM) generates absorbance at 600-650 nm allowing for fluorescence (dotted red 
line) at 660 nm. 
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3.8 Discussion 
This Chapter describes the synthesis of 5 caged fluorophores which were 
produced in high yield using a one-step esterification in pyridine. It was found that 
naphthofluorescein and resorufin required 4 equivalents of fatty acyl chloride to drive this 
reaction and achieve a color change.  DDAO required only 2 equivalents of fatty acyl 
chloride for both arachidonate and palmitate probes.  In addition, both arachidonate and 
palmitate reaction yields were higher for DDAO conjugation versus resorufin 
conjugation.  This difference in reactant concentrations did not appear to correlate with 
reaction yield as naphthofluorescein diarachidonate had the highest yield (98 %) and 
resorufin palmitate had the lowest (14.3 %).  However, the reaction yield did appear to be 
influenced by both fatty acid and fluorophore.  For both resorufin and DDAO, the 
reaction yield was higher for arachidonate conjugates (19.9% and 65 %, respectively) 
versus palmitate conjugates (14.3% and 33%, respectively). Despite this observation, 
reaction yields are a function of many factors and the observed differences between 
fluorophores and fatty acid may be related to differences in starting material purity, 
adding temperature, side reactions such as dehydrochlorination, along with unidentified 
mechanisms. 
The colored nature of these compounds allowed for easy visual monitoring of 
both reaction progress and separation using column chromatography.  The use of U.V. 
light to monitor progress in the column increased the ability to visually separate product 
from starting material.  Because the product traveled faster than the starting material, it 
was possible to adjust the ratio of hexanes/ethyl acetate in each synthesis in real time in 
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order to maximize separation.  Following purification of individual probes with column 
chromatography, structures were confirmed with mass spectrometry and 
1
H nuclear 
magnetic resonance (
1
H NMR). Because of the asymmetry present in the fluorophore 
DDAO, two tautomeric forms arising from proton transfer between the hydroxyl and 
ketone groups are possible. However, despite this tautomerization, 
1
H NMR analysis did 
not show a mixture of isomers indicating only one product was obtained. Previous 
literature indicated that substitution of the hydroxyl on the chlorinated ring occurred to a 
much higher extent (Warther et al. 2010, Duo, Goddard-Borger, and Withers 2014). 
 All fluorophores demonstrated the ability to be quenched through fluorescence 
measurements in protonated vs. unprotonated states.  In addition, hydrolysis with NaOH 
demonstrated the ability to restore fluorescence for each esterified fluorophore.  For 
DDAO arachidonate, we demonstrated that a pancreatic phospholipase, sPLA2 GIB, can 
also lead to probe activation. This will be explored in more detail in Chapter 4. 
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Chapter 4: In Vitro Evaluation of Probe Activation and Specificity 
4.1 Introduction 
 cPLA2 is overexpressed in numerous cancers and is implicated in the 
development of resistance to estrogen receptor targeted therapy of breast cancer (Caiazza, 
Harvey, and Thomas 2010, Murakami et al. 2011, Meyer et al. 2004, Hong et al. 2001).  
In breast cancer, cPLA2 expression is correlated to the molecular subtype, with higher 
expression in basal-like cancer versus luminal-like cancer (Caiazza et al. 2011).  In 
addition, levels of the downstream metabolite of cPLA2, glycerophosphocholine (GPC), 
have been found to be elevated in basal-like compared to luminal-like breast cancer, and 
this has been linked to elevations in cPLA2 gene expression (Moestue et al. 2010). 
 Molecular imaging of cancer offers the potential to probe alterations in enzyme 
expression and activity in vivo, providing potentially relevant functional information for 
clinical assessment.  In a research setting, molecular imaging agents allow for the 
elucidation of unknown biological tumor pathways and can serve as companion 
diagnostics for the development of novel therapeutics (Weissleder 2006, Willmann et al. 
2008).  Activatable fluorophores for molecular imaging have been of increased interest 
(Tung et al. 2004, Kamiya et al. 2007, Beatty et al. 2013, Setsukinai et al. 2003, Urano et 
al. 2011).  In contrast to targeted fluorophores, which rely on selective tumor 
accumulation in combination with rapid systemic clearance to facilitate contrast, 
activatable fluorophores generate high signal to noise due to selective activation in areas 
of interest, typically through specific enzymatic cleavage (Rao, Dragulescu-Andrasi, and 
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Yao 2007).  This allows for the cleavage of multiple fluorescent substrates resulting in 
increased signal amplification and high detection sensitivity.  In addition, this provides 
the ability to quantitate target activity in addition to enzyme expression. 
Activatable fluorophores have been previously targeted towards phospholipases C 
and A2 through incorporation of fluorophores and complimentary quenchers into the 
backbone of a phospholipid (Popov et al. 2010, Mawn et al. 2011).  In the design for 
PLC, Pyropheophorbide a (Pyro), a NIR fluorophore, was esterified to the sn-2 position 
and the head group was replaced with the NIR black hole quencher, BHQ-3. Further 
alteration of this structure found that incorporation of a 12-carbon spacer between Pyro 
and the glycerol backbone shifted specificity away from PLC and towards sPLA2 group 
IB.  Utilizing this probe design to generate a cPLA2 selective agent proved challenging.  
cPLA2 structural based analysis has identified a small pocket where the head group lies 
during lipolysis and it is likely a large quencher would decrease activity (Dessen et al. 
1999).  In addition, arachidonic acid at the sn-2 position would be necessary to generate 
specificity for cPLA2.  Therefore, a simpler probe design was needed. 
 Previous studies have shown that a caged fluorescent molecule, 7-HC is cleavable 
by purified cPLA2 resulting in the generation of fluorescence (Huang et al. 1994, Pickard 
et al. 1996).  The fluorescence release occurred at an identical rate to enzymatic cleavage 
of 
14
C-labeled endogenous phospholipids, suggesting that the glycerol backbone and head 
group are not absolutely required for cPLA2-mediated cleavage.  Due to the chemical 
nature of fluorescence quenching, in which covalent molecular bonding alters the 
delocalized electronic structure necessary for fluorescence, caged fluorophores can 
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theoretically achieve higher levels of quenching than spatially FRET or contact quenched 
fluorophores, thus minimizing background signal.  However, the low wavelength 
emission of 7-HC limits its in vivo potential.  Fluorophores which fluoresce in the NIR 
window, a region of the electromagnetic spectrum with minimal absorption from 
hemoglobin and water, are more suitable for in vivo imaging (Weissleder 2001). 
 In this Chapter, we assess the three cPLA2 caged red-shifted fluorophores, 
described in Chapter 3, which were synthesized based on the design of 7-HC.  In 
addition, we assess the functionality of the two control probes in which palmitic acid was 
esterified.  Synthesized caged fluorophores contain only a fatty acid esterified to a small 
molecule fluorophore, therefore it must be evaluated for each fluorophore whether 
phospholipase activation can occur without the presence of a glycerol backbone and 
phosphorylated head group.  Due to the ability of purified cPLA2 to cleave 7-HC, we 
hypothesized that similar small molecule fluorophores esterified to a fatty acid will also 
be cleavable by PLA2.  Additionally, we hypothesized that arachidonic acid, but not 
palmitic acid, incorporated fluorophores will be cleavable by cPLA2. 
Using purified porcine group IB sPLA2 (sPLA2 GIB), which has no specificity 
for arachidonic acid, we first assessed the activatable fluorophores for their ability to 
undergo enzyme-mediated cleavage in vitro.  We then assessed whether incorporation of 
arachidonic acid conferred selectivity towards cPLA2 in live cell assays using breast 
cancer cell lines that express high levels of cPLA2.  The enzymatic specificity to cPLA2 
was assessed using inducing agents and inhibitors of the enzyme.  In addition, we probed 
whether varying the degrees of cPLA2 expression correlates with probe activation.  In 
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breast cancer, it has been shown that cPLA2 varies with breast cancer subtype, with 
basal-like cancer expressing higher levels than luminal-like cancer (Caiazza et al. 2011).  
We therefore used cell lines representing the three major subtypes of breast cancer to 
evaluate whether activity correlates with cPLA2 expression.  Finally, we utilized Cluster 
Regularly Interspaced Short Palindromic Repeats (CRISPR) knockdown to more 
specifically assess the role of cPLA2 in probe activation. 
The fatty acid caged fluorophores are not soluble in aqueous media.  Therefore a 
method of solubilization was needed for delivery and enzymatic evaluation.  Since 
cPLA2 acts preferentially on phosphatidylcholine rich biological membranes (Murakami 
et al. 2011), we decided to use artificial phosphatidylcholine rich liposomes for in vitro 
analysis with purified enzyme. Egg phosphatidylcholine liposomes were therefore used 
as a delivery vehicle for phospholipase probes.  For in vitro studies, egg 
phosphatidylcholine liposomes were generated (see Chapter 2: Methods) with the probe 
incorporated at a mole fraction of 0.1.  For experimental studies the amount of agent 
added is referred to in nmol of activatable probe. 
4.2 Results 
Activation in the presence of sPLA2 GIB  
sPLA2 GIB is a pancreatic digestive enzyme that functions to break down 
ingested phospholipids for intestinal absorption (Dennis et al. 2011).  sPLA2 GIB has no 
specificity for incorporated fatty acids, however it has high phospholipase activity.  
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Therefore, using purified sPLA2 GIB, we evaluated the ability of synthesized caged 
fluorophores to undergo phospholipase-mediated cleavage.   
To test for sensitivity to phospholipase cleavage, 1 nmol of probe was incubated 
with varying concentrations of sPLA2 GIB in pH 7.4 Tris buffer containing 1.1 mM 
CaCl2.  Fluorescence generation was monitored as a function of time (Figure 4.1). 
Naphthofluorescein diarachidonate displayed a low initial fluorescence (Figure 4.1A).  
Figure 4.1. Cleavage and fluorescence generation of candidate probes by a nonselective 
phospholipase (sPLA2 GIB). Fluorescence generation is shown with time in the presence of increasing 
concentrations of sPLA2 GIB for naphthofluorescein arachidonate (A), resorufin arachidonate (B), 
resorufin palmitate (C), DDAO arachidonate (D), and DDAO palmitate (E). One unit is equivalent to the 
amount of enzyme producing 1 μmol of free fatty acid per minute at pH 8 and at 40 °C. 
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Addition of sPLA2 GIB resulted in increased fluorescence generation that positively 
correlated with enzyme concentration.  However, the relative fluorescence units (R.F.U.) 
were low, remaining under 20 R.F.U. even for the maximum concentration of enzyme 
added.   
Resorufin arachidonate and resorufin palmitate both resulted in increased 
fluorescence with time, which was positively correlated with the concentration of sPLA2 
GIB (Figure 4.1B,C).  A high initial fluorescence was observed in both arachidonate and 
palmitate activation studies.  Initial fluorescence was higher in the presence of enzyme 
than in control wells without added phospholipase.  However, even in enzyme-free 
controls, initial fluorescence was fairly high and increased with time. 
 DDAO arachidonate and palmitate both showed activation in the presence of 
sPLA2 GIB that positively correlated with enzyme concentration (Figure 4.1D,E). Initial 
fluorescence of both DDAO arachidonate and DDAO palmitate was low (less than 100 
R.F.U.), and a significant time-dependent increase in fluorescence was observed in the 
presence of sPLA2 (p = 5.7 × 10
−26
 and p = 2.8 × 10
−14
, respectively, for 100 units sPLA2 
at 720 min). 
In order to confirm that DDAO arachidonate and palmitate fluorescence 
activation resulted directly from phospholipase activity, experiments were performed 
using a sPLA2 inhibitor, LY311727 (Figure 4.2). In the presence of LY311727, 
fluorescence generation was reduced for both probes (Figure 4.2A,B). Quantitation of the 
final fluorescence intensity at 720 min (Figure 4.2C) showed that both DDAO 
arachidonate and DDAO palmitate fluorescence were significantly (p = 1.4 × 10
−11
 and p  
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= 3.2 × 10
−7
, respectively) reduced in the presence of LY311727. The final fluorescence 
intensity of DDAO arachidonate was not significantly different from that of DDAO 
palmitate.  Due to the high degree of activation, high initial quenching, and low aqueous 
Figure 4.2. DDAO fluorescence generation is attenuated by the sPLA2 inhibitor LY311727. The 
fluorescence generated by 100 units of sPLA2 was inhibited by the addition of 100 μM of the sPLA2 
inhibitor LY311727 for both DDAO arachidonate (A) and DDAO palmitate (B). (C) Quantifying the 
fluorescence at 720 min shows that LY311727 significantly inhibits the final fluorescence intensity of 
DDAO arachidonate (p = 1.4 × 10
−11
) and DDAO palmitate (p = 3.2 × 10
−7
 ). In the absence of enzyme, 
DDAO arachidonate gives significantly higher fluorescence (p = 3.1 × 10
−11
) than DDAO palmitate. No 
significant difference exists in the final fluorescence between DDAO arachidonate and DDAO palmitate 
in the presence of 100 units of sPLA2. 
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hydrolysis observed, DDAO arachidonate was chosen for future analysis of cPLA2 
activity in combination with the control probe, DDAO palmitate.  
Optimization of liposomal formulation 
In order to optimize DDAO arachidonate activation and to minimize aqueous 
hydrolysis, the formulation of the liposomes was varied and probe cleavage in the 
presence of sPLA2 GIB was assessed.  Delivery of probe in DMSO was also assessed as 
an additional control.  In all cases, the 
concentration of probe was kept constant 
at 0.2 nmol of probe per well in a 96 well 
plate.  Mole fractions of 0.01, 0.05, 0.1, 
and 0.2 were tested (Figure 4.3).    
There were no large differences in 
aqueous mediated hydrolysis for all 
conditions tested including a DMSO 
vehicle control (Figure 4.3A).  However, a 
high difference in cleavage sensitivity was 
noted when incubated in the presence of 
100 units sPLA2 GIB (Figure 4.3B).  It 
was observed that a DDAO arachidonate 
mole fraction of 0.05 resulted in the 
highest levels of cleavage.  Increasing the 
mole fraction to 0.1 or 0.2 resulted in  
Figure 4.3. Optimization of liposomal 
formulation.  A) Aqueous hydrolysis of DDAO 
arachidonate incorporated into egg 
phosphatidylcholine liposomes at varying mole 
fractions.  B) sPLA2 mediated hydrolysis (100 
Units) of DDAO arachidonate incorporated into 
liposomes of varying mole fractions. 
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Figure 4.4. Cellular activation of DDAO arachidonate and DDAO palmitate. DDAO 
arachidonate and DDAO palmitate were incubated with 4175-Luc+ cells for 30 min (A) 
and for 3 h (B). Wide field fluorescent microscopy was performed to visualize free 
DDAO fluorescence. Nuclei were counterstained with Syto 9. Separate and merged 
fluorescence images are shown with yellow indicating overlap of fluorescence in the 
merged image. (C) Fluorimetry was used to quantify DDAO fluorescence as a function of 
time and demonstrated significantly increased fluorescence at 3 h from DDAO 
arachidonate relative to DDAO palmitate (p = 1.3 × 10
−6
 ). 
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decreased fluorescence generation with time.  The DDAO arachidonate / DMSO vehicle 
control showed slow activation with time that was comparable to aqueous  
mediated hydrolysis.  This is consistent with PLA2 requiring a phospholipid membrane 
in order to act. Egg phosphatidylcholine liposomes with a mole fraction of 0.05 probe 
were further assessed for the effects of extrusion on fluorescence generation.  Liposomes 
were prepared as previously described (see Chapter 2: Methods) and then subjected to 
extrusion through a sterile 0.2 µm filter.  Following extrusion it was found that 
fluorescence activation in the presence of sPLA2 was significantly decreased (data not 
shown).  Therefore, polydisperse liposomes without extrusion were used in future 
experiments at a mole fraction of  0.05.  Dynamic light scattering indicating an average 
size of 295.55 nm with a polydispersity of 187.65 nm. 
DDAO arachidonate activation in a cPLA2 expressing breast cancer cell line 
The activity of DDAO arachidonate was further evaluated in a breast cancer cell 
line expressing high levels of cPLA2.  4175-Luc+ is a triple-negative breast cancer cell 
line derived from a murine lung metastasis of the MDA-MB-231 line and engineered to 
express luciferase (Minn et al. 2005). MDA-MB-231 cells have previously been shown to 
have increased cPLA2 activity consistent with the increased cPLA2 expression in triple 
negative basal-like breast cancer (Caiazza, Harvey, and Thomas 2010). 4175-Luc+ cells 
were incubated with DDAO arachidonate or DDAO palmitate for up to 3 h and co-
stained with the nuclear stain Syto 9. The cells were analyzed with wide field 
fluorescence microscopy (Figure 4.4). At 30 min, weak intracellular fluorescence from 
DDAO arachidonate was observable with no fluorescence visible from DDAO palmitate 
(Figure 4.4 A). At 3 hours, strong intracellular fluorescence was seen from DDAO 
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arachidonate; however, there was still no fluorescence in cells incubated with DDAO 
palmitate. DDAO arachidonate fluorescence was dispersed throughout the cytoplasm but 
with high perinuclear fluorescence, consistent with the subcellular location of cPLA2 
activity (Figure 4.4B). In order to quantitate activation, the experiment was repeated 
using fluorimetry to measure fluorescence (ex/em: 600/660 nm) with time (Figure 4.4C). 
Quantitation showed a strong time-dependent increase in fluorescence in cells incubated 
with DDAO arachidonate, whereas little change was observed in DDAO palmitate 
incubated cells. Unlike the nonselective sPLA2 GIB cleavage studies shown in Figure 
4.2, DDAO arachidonate displayed a significantly (p = 1.3 × 10
−6
) higher final 
fluorescence intensity in cells compared to that of DDAO palmitate. 
In order to visualize the time dependence of fluorescence activation, a wide field 
fluorescence microscope (EVOS FL Auto) equipped with a 37°C stage and a 5% CO2 
incubation chamber was utilized.  Following addition of DDAO arachidonate, the plate 
was placed in the chamber for 30 minutes to adjust to the environment.  Fluorescence 
activation was then measured over the course of 70 minutes (Figure 4.5A,B). Small 
vesicles with high fluorescence were seen to appear and then disappear as fluorescence 
became dispersed throughout the cytoplasm.  Vesicles appeared to be localized around 
the peri-nuclear region where cPLA2 is known to act (Evans et al. 2001, Nakamura et al. 
2010).  In one cell, vesicles can be seen forming initially close to the nucleus, then 
migrated out towards the cytoplasm and dispersing (Figure 4.5B). 
To determine whether the observed differences in probe activation were the result 
of cPLA2, two agents that induce cPLA2 activity were employed: ionomycin and  
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Figure 4.5. DDAO arachidonate activation with time.  Wide field fluorescence microscopy 
was used to visualize the subcellular activation of DDAO arachidonate with time.  DDAO 
activation is shown in red, Syto 9 nuclear staining is shown in green.  A) Fluorescence 
accumulation can be seen with time dispersed throughout the cytoplasm and in small vesicles 
surrounding the nucleus  B) Cellular activation of DDAO arachidonate in one cell showed initial 
appearance of bright vesicles surrounding the nucleus which migrated to the cytoplasm resulting 
in dispersed fluorescence accumulation. 
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hydrogen peroxide. Ionomycin is a calcium ionophore, which when incubated with cells 
leads to calcium release from intracellular stores into the cytosol. cPLA2, which resides 
in the cytosol, requires calcium for translocation to membranes where it can act on 
membrane localized phospholipids (Burke and Dennis 2009, Murray-Whelan et al. 1995). 
 
Figure 4.6. cPLA2 enzymatic induction and inhibition. cPLA2 activity was induced through either 
H2O2 (A) or ionomycin (B). Fluorescence generation was monitored with time. DDAO arachidonate 
showed significant enhancement of fluorescence in the presence of H2O2 (p = 2.9 × 10
−6
 ) and ionomycin 
(p = 1.9 × 10
−7
 ), whereas DDAO palmitate did not show any significant changes in fluorescence. (C) 
Phospholipase inhibitors were incubated with cells for 4 h, cells were washed in PBS, and fresh medium 
containing either DDAO arachidonate or DDAO palmitate was added. Fluorescence was recorded 
following 30 min of incubation. AACOCF3 treatment resulted in a significant (p = 0.003) reduction of 
fluorescence relative to that of the control. BEL and LY311727 did not alter fluorescence significantly. 
No significant changes in fluorescence were recorded in the presence of DDAO palmitate. 
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Previous work has indicated hydrogen peroxide is a potent activator of cPLA2 activity, 
partly due to phosphorylation through the MAPK pathway (van Rossum et al. 2004). 
Incubation of 4175-Luc+ cells with either ionomycin (2 μM) or hydrogen peroxide (300 
μM) in the presence of DDAO arachidonate resulted in a significant (p = 1.9 × 10−7 and p 
= 2.9 × 10
−6
, respectively) increase in the final relative fluorescence (Figure 4.6A,B). 
However, neither ionomycin nor hydrogen peroxide had a significant effect on DDAO 
palmitate fluorescence. It was noted that at 3 h, cells treated with ionomycin began 
showing signs of stress, most notably rounding of the cells and detachment from the plate 
to a small extent. It is possible that the slight nonsignificant increase in DDAO palmitate 
fluorescence could be attributed to increased light penetration resulting from rounded up 
cells. Phospholipase specificity was further evaluated by monitoring fluorescence 
following incubation with several phospholipase inhibitors (Figure 4.6C). Inhibitors were 
added to 4175-Luc+ cells for 4 h at a concentration of 10 μM, cells were then washed in 
PBS, and fresh medium containing either DDAO arachidonate or DDAO palmitate was 
added. Fluorescence (ex/em: 600/660 nm) was measured following 30 min of incubation. 
Arachidonyl trifluoromethyl ketone (AACOCF3), a cPLA2 and iPLA2 selective 
inhibitor, resulted in a significant reduction in DDAO arachidonate fluorescence 
compared to that of untreated controls (p = 0.003). Bromoenol lactone (BEL), an iPLA2 
selective inhibitor, resulted in no significant change in fluorescence. These data indicate 
that the fluorescence inhibition caused by AACOCF3 is a direct result of cPLA2 activity 
and not iPLA2 activity. In vitro studies (Figures 4.1 and 4.2) indicated that DDAO 
arachidonate is also susceptible to cleavage by sPLA2. Therefore, to control for sPLA2 
selective activation, the sPLA2 inhibitor LY311727 was used. A small decrease in 
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fluorescence was witnessed in the presence of LY311727; however, this was not 
significant. DDAO palmitate gave no significant changes in fluorescence in the presence 
of any of the inhibitors. 
To further evaluate the specificity of DDAO arachidonate, a highly potent cPLA2 
inhibitor, AVX-235, was used.  Cells were incubated with 10 µM AVX-235 for two 
hours prior to analysis.  DDAO arachidonate or DDAO palmitate was added to initiate 
 
Figure 4.7. Inhibition of DDAO arachidonate by AVX-235.  DDAO arachidonate and DDAO palmitate 
activation was measured as a function of time in 4175-Luc+ cells in the presence of 10 µM AVX-235, a 
potent cPLA2 inhibitor, or DMSO vehicle control.  A significant decrease (p=0.006) of fluorescence 
corresponding with 20% inhibition was observed for DDAO arachidonate.  No significant changes were 
seen for DDAO palmitate. 
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the reaction and fluorescence generation was monitored with time.  AVX-235 resulted in 
a significant inhibition in the generation of fluorescence with time (p=0.006) with no 
significant inhibition of DDAO palmitate (Figure 4.7). 
Activation of DDAO arachidonate in varying breast cancer subtypes 
DDAO arachidonate was evaluated in a series of breast cancer cell lines 
previously described to differ in their expression of cPLA2.  Three breast cancer cell 
lines were chosen to represent the three major subtypes of breast cancer.  MDA-MB-231 
is a basal-like cell line representing triple negative breast cancer.  SKBR3 is a HER2 
expressing cell line representing HER2-like breast cancer.  MCF-7 is a estrogen receptor 
positive cell line representing luminal-like 
breast cancer.  In addition, we also used the 
4175-Luc+ cell line, a metastatic derivative 
of the MDA-MB-231 cell line, which is 
highly tumorigenic. 
Cell lines were analyzed by 
immunoblot to determine the relative 
protein levels of cPLA2 (Figure 4.8).  
Consistent with previous literature, it was 
found that MCF-7 cells contain the lowest 
levels of cPLA2, with SKBR3 cells having 
two fold higher expression and MDA-MB-
Figure 4.8.  Immunoblot of cPLA2 in breast 
cancer cell lines.  A) cPLA2 and β-tubulin protein 
expression levels. B) Quantitated ratio of cPLA2 / 
β-tubulin. 
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231 cells having six fold higher expression.  4175-Luc+ cells have the highest cPLA2 
expression, even greater than the parent cell line, MDA-MB-231. 
 To determine whether cellular protein levels correlated with cPLA2 activity we 
seeded cells in 96 well black-wall clear bottom plates at concentrations optimized to 
achieve ~80% confluency in 48 h.  To test for specificity, the cPLA2 inhibitor AVX-235 
or vehicle control was added 2 hours prior to the addition of either DDAO arachidonate 
or DDAO palmitate.  Fluorescence was measured at four hours using the LI-COR 
Odyssey
®
 CLx imaging system (700 nm channel) and quantitated relative to the mg of 
protein present per well determined using a Qubit
®
 protein assay (Figure 4.9).  4175-
Luc+ gave the highest fluorescence activation of DDAO arachidonate, followed by 
MDA-MB-231.  SKBR3 displayed fluorescence less than that of MDA-MB-231 and 
MCF-7 cells displayed the lowest relative fluorescence.  AVX-235 significantly inhibited 
the fluorescence of 4175-Luc+ and MDA-MB-231 (p = 0.006 and 0.03, respectively).  A 
trend towards reduced fluorescence was seen for SKBR3 and MCF-7 cells in the 
presence of AVX-235, however this was not significant.  In all cases, DDAO palmitate 
fluorescence was significantly less than that of DDAO arachidonate.  Using the 
assumption that DDAO palmitate activation is a function of non-cPLA2 mediated 
hydrolysis, the R.F.U. / mg protein was adjusted by subtraction of the DDAO palmitate 
fluorescence and plotted as relative cPLA2 activity (Figure 4.10A).  A close correlation 
(R
2
 = 0.9633) between fluorescence activation and protein expression can be seen (Figure 
4.10B). 
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In order to confirm that measured signal is a result of cellular activation, we 
repeated this study in the MDA-MB-231, SKBR3, and MCF-7 cell lines using confocal 
fluorescence microscopy (Figure 4.11).  Images were acquired at 4 hours and analyzed 
with Image J.  MDA-MB-231 resulted in the brightest fluorescence, followed by SKBR3, 
with MCF-7 cells displaying the lowest fluorescence generation.  AVX-235 treatment 
resulted in decreased fluorescence in all cell lines for DDAO arachidonate.  As observed 
with spectroscopy, cells treated with DDAO palmitate displayed weak fluorescence 
making visualization difficult. 
Figure 4.9. Inhibition of cPLA2 in a panel of breast cancer cell lines with AVX-235.  Four breast 
cancer cell lines representing the three most common breast cancer subtypes were incubated with DDAO 
arachidonate or DDAO palmitate in the presence or absence of 10 µM AVX-235, a potent cPLA2 
inhibitor.  Fluorescence was acquired after four hours on a LI-COR Odyssey CLx imaging system (700 
nm channel).  Significant inhibition of DDAO arachidonate  was observed for 4175-Luc+ and MDA-MB-
231 cells when incubated with AVX-235 (p = 0.006 and 0.03, respectively).  No significant changes in 
DDAO palmitate fluorescence were observed in all cell lines analyzed. 
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 Analysis of images costained with nuclear HOESCHT2388 reveals differences in 
cytosolic distribution of fluorescence (Figure 4.12).  MDA-MB-231 cells display 
fluorescence evenly dispersed throughout the cytosol.  SKBR3 displays fluorescence 
concentrated in small cytosolic vesicles.  MCF-7 displays low cytosolic fluorescence and 
uniquely shows evenly dispersed fluorescence in the cellular membrane. 
 Finally, a genetic knockdown using Cluster Regularly Interspaced Short 
Palindromic Repeats (CRISPR) technology was generated through transfection of 4175-
Luc+ cells with a cPLA2 targeted knockout vector (Santa Cruz Biotechnology).  This 
vector encoded for CRISPR associated protein 9 (Cas9), 3 Cas9 guide RNAs targeted 
towards cPLA2, and green fluorescent protein (GFP) (Figure 4.13A).  Positively 
transfected cells, determined through the expression of GFP, were separated using 
fluorescence-activated cell sorting (Figure 4.13B).  Cells were expanded and analyzed for 
protein expression (Figure 4.14A).  A significant reduction in cPLA2 expression 
(approximately 40%) was observed in CRISPR treated cells versus non-transfected.  
DDAO arachidonate and DDAO palmitate activation within these cells was determined 
with time (Figure 4.15A) and cPLA2 activity was quantitated at 120  min (Figure 4.15B).  
A significant decrease in fluorescence was observed in cells treated with CRISPR/Cas9 
knockout vector (p = 1.58 x 10
-6
).   
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Figure 4.10.  cPLA2 activity in breast cancer cell lines.  A) cPLA2 activity in breast cancer cell lines 
was calculated from Figure 4.9 by subtracting non-selective cleavage from the fluorescence of DDAO 
palmitate.  B) Activity levels relative to 4175-Luc+ were plotted versus cPLA2 expression relative to 
4175-Luc+ (taken from Figure 4.8).  A close correlation (R
2
 = 0.9633) between activity and expression 
was observed.  
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Figure 4.11.  Confocal fluorescence microscopy of DDAO arachidonate and palmitate 
activation and inhibition.  Fluorescence at four hours is shown as a heat map with brighter areas 
indicating high fluorescence signal. 
Figure 4.12.  Confocal fluorescence microscopy of the subcellular distribution of DDAO 
arachidonate.  Fluorescence at four hours with DDAO fluorescence in green, and HOESCHT 
33342 nuclear staining in blue.  Images are not optimized for intensity comparison but for analysis 
of subcellular distribution. 
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Figure 4.13.  cPLA2 genetic knockdown through CRISPR/Cas9.  A) A cPLA2 targeted CRISPR/Cas9 
vector encoding Cas9, 3 cPLA2 targeted guide RNAs, and GFP was purchased from Santa Cruz 
Biotechnology.  A vector containing scrambled guide RNAs was also purchased.  B) Vector was 
transfected into 4175-Luc+ cells and GFP expressing cells were separated using fluorescence-activated 
cell sorting.  A fluorescence cut-off of 10
2
 was chosen based on the auto-fluorescence of non-transfected 
cells (neg) and positive populations of cPLA2 (cPLA2) and scrambled (Ctrl) transfected cells were 
isolated. 
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4.3 Discussion  
In this Chapter, we determined the sensitivity of our synthesized DDAO probes to 
phospholipase activation using purified enzyme and cells. Prior to the analysis for 
specificity to cPLA2 activation, it needed to be ascertained whether all probes, including 
the palmitic acid controls, were susceptible to phospholipase mediated cleavage.  To 
determine this, the probes were tested against sPLA2 GIB, a pancreatic digestive 
phospholipase with no specificity towards arachidonic acid.  It was observed that all 
probes were activated with time in proportion to the concentration of sPLA2 added.  
Similar to what was observed in the literature for 7-HC (Huang et al. 1994), these data 
supports the concept that a glycerol backbone and phosphorylated head group are not 
Figure 4.14.  cPLA2 expression in CRISPR transfected cells.  A) Immunoblot of cPLA2 and β-
tubulin in non-transfected, cPLA2 CRISPR transfected, and scrambled CRISPR transfected cells.  B) 
Quantitation of relative cPLA2 expression in cell lines.  Significant reduction of protein expression is 
observed for cPLA2 transfected cells (p = 8.2 x 10
-7
). 
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necessary for probe activation by PLA2.  However, modification of the fluorophore and 
fatty acid both led to observable effects on the degree of cleavage. 
Naphthofluorescein diarachidonate displayed poor enzymatic activation, with the 
final fluorescence intensity remaining under 20 R.F.U.s, even for the maximum 
concentration of enzyme added.  Naphthofluorescein diarachidonate was the largest 
fluorophore synthesized, and it is possible that steric hindrance contributed to poor 
enzymatic cleavage.  In addition, naphthofluorescein has a pKa of 7.6, which may 
contribute to the poor relative fluorescence observed at pH 7.4.  At a pH of 8.0, it was 
possible to increase the relative fluorescence generation 9-fold.  Because of these 
observed limitations, a naphthofluorescein dipalmitate control probe was not synthesized. 
Resorufin arachidonate and resorufin palmitate both gave increased fluorescence 
generation with time.  However, a high initial fluorescence was observed indicating either 
poor intramolecular quenching or rapid enzymatic hydrolysis.  Even in controls 
conducted without the addition of enzyme, initial fluorescence was fairly high and 
increased over time.  This would indicate that resorufin-conjugated fatty acids may be 
susceptible to nonspecific aqueous hydrolysis in addition to enzymatic cleavage. 
Similar to resorufin, DDAO arachidonate and palmitate both gave increased 
fluorescence activation with time.  Initial fluorescence of both DDAO arachidonate and 
DDAO palmitate was low (less then 100 R.F.U.) indicating a high degree of initial 
fluorescence quenching.  In addition, minimal aqueous hydrolysis was observed 
indicating DDAO arachidonate would be likely to give the largest signal to noise ratio. 
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The large difference in initial fluorescence observed between DDAO and 
resorufin conjugates may be due to steric or electrostatic protection by the two chloride 
groups ortho to the ester bond in DDAO.  This is consistent with previous literature 
showing that 2,6-dichlorophenyl acetate has a hydrolysis constant that is 1.5 times lower 
than that of phenol acetate (Nottebohm 2010).  For DDAO arachidonate, a more rapid 
initial rate of fluorescence activation was observed compared to the palmitate probe, 
suggesting that arachidonate conjugation results in a more readily hydrolyzable 
fluorophore.  Because of DDAO’s high initial quenching and significant increase in 
Figure 4.15.  DDAO arachidonate and DDAO palmitate activation in CRISPR transfected cell lines.  
A) Activation with time of DDAO arachidonate and DDAO palmitate in cPLA2, scrambled, and non-
transfected cells.  B)  Quantitation of relative fluorescence at 120 min showing significant reduction in 
cPLA2 targeted CRISPR transfected vector (p = 1.58 x 10
-6
) 
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fluorescence versus other fluorophores, it was chosen as our candidate cPLA2 probe for 
further studies. 
Inhibition of sPLA2 with LY311727 resulted in a significant decrease in the 
generation of DDAO arachidonate and DDAO palmitate generated fluorescence 
indicating activation is a direct result of enzyme activity.  The final fluorescence intensity 
was not significantly different between DDAO arachidonate and palmitate probes 
indicating both probes are hydrolyzed to the same degree, albeit at different rates.  As 
expected, because sPLA2 GIB has no selectivity for arachidonic acid, no difference in 
final fluorescence was observed.  However, DDAO arachidonate in the absence of 
enzyme did give significantly (p = 3.1 x 10
-11
) higher fluorescence than that of DDAO 
palmitate indicating that DDAO arachidonate may be more sensitive to aqueous 
hydrolysis.  This may be an additional factor contributing to the differing rates of 
enzymatic hydrolysis observed. 
In a triple negative breast cancer cell line expressing high levels of cPLA2, 
fluorescence generation in the presence of DDAO arachidonate and DDAO palmitate was 
assessed with fluorescence microscopy and spectroscopy.  To minimize the presence of 
sPLA2, cells were washed 2x with PBS immediately prior to addition of probe.  It was 
observed that unlike sPLA2 mediated cleavage studies, breast cancer cells led to 
significantly increased activation of DDAO arachidonate relative to DDAO palmitate.  
Microscopy showed that the activation occurred intracellularly, with probe dispersed 
throughout the cytoplasm but with high perinuclear fluorescence, consistent with the 
subcellular location of cPLA2.  The final fluorescence intensity, measured with 
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fluorescence spectroscopy, was noted to be lower than the relative fluorescence achieved 
through in vitro studies.  This may be attributed to a combination of increased scattering 
and absorption of light by cells and differences in enzyme concentration, along with 
variations in cellular uptake.  However, these results indicate that DDAO arachidonate 
was specifically activated in 4175-Luc+ breast cancer cells, whereas DDAO palmitate 
was not. 
The specificity of the cPLA2 activity was probed through the use of cPLA2 
inducing agents and inhibitors.  Ionomycin and hydrogen peroxide, two known inducers 
of cPLA2 resulted in a significant increase of DDAO arachidonate fluorescence but not 
DDAO palmitate.  AACOCF3, a mixed inhibitor for cPLA2 and iPLA2, resulted in 
significant reduction of fluorescence generation implicating either cPLA2 or iPLA2 to be, 
at least partially, responsible for cleavage.  BEL, an iPLA2 selective inhibitor, had no 
effect on fluorescence generation, nor did LY311727, a sPLA2 selective inhibitor.    In 
addition, we explored the use of a highly potent cPLA2 inhibitor, AVX-235.  In repeating 
DDAO activation in the presence of inhibitor, we found a higher percentage of 
fluorescence inhibition, compared to that with AACOCF3, was achievable with AVX-
235.  Together these results suggest that although DDAO arachidonate is susceptible to 
sPLA2 mediated cleavage in vitro, the fluorescence observed in cancer cells directly 
results from cPLA2 activity.  DDAO palmitate, being activated by sPLA2 to the same 
extent as DDAO arachidonate, but not by cPLA2, served as a useful control for 
nonselective cleavage when assaying cPLA2 activity.  This was used further to assess 
differences in cPLA2 in breast cancer subtypes. 
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cPLA2 has been shown to vary in breast cancer subtypes with higher expression 
in basal-like vs. luminal-like cancer.  Through immunoblot analysis, we measured cPLA2 
expression in four breast cancer cell lines ranging in molecular subtype.  In agreement 
with previously reported studies (Caiazza, Harvey, and Thomas 2010), we found that 
triple negative breast cancer cells had the highest cPLA2 expression, HER2 expressing 
cells had intermediate expression, and luminal-like cells had low expression.  Analysis of 
DDAO arachidonate activation in these cell lines correlated closely with relative cPLA2 
expression levels, thus lending further evidence to the specificity of DDAO arachidonate 
for cPLA2.   
Inhibition of cPLA2 in cell lines using the inhibitor AVX-235 was shown to 
significantly decrease the fluorescence generation of DDAO arachidonate in 4175-Luc+ 
and MDA-MB-231 cells.  Although a trend towards decreased fluorescence was seen in 
MCF-7 and SKBR3 cells, this was not significant.  It is likely the lower fluorescence 
signal present in MCF-7 and SKBR3 decreases the ability to measure significant 
inhibition.  When experiments were repeated using fluorescence confocal microscopy, a 
clear drop in fluorescence was observed in all cell lines when incubated with AVX-235.   
Confocal microscopy of the cell lines provided valuable insight into the 
variability that is present in the sub-cellular location of DDAO arachidonate activation.  
Differences in vesicle appearance and activation between cell lines may be an effect of 
time, as was observed in Figure 4.5.  The nature of these vesicles requires further 
investigation.  Liposomes can be incorporated into cells through two main processes 
(Düzgünes and Nir 1999).  Membrane fusion can occur between the cellular membrane 
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and the liposomal membrane resulting in dispersion of probe throughout the cell.  
Alternatively endocytosis of liposomes followed by fusion or lipid exchange could occur.  
Depending on the extent of lipid exchange which occurs, transfer to lysosomal vesicles 
and subsequent degradation is also possible and may be a cause of non-specific 
activation.  The presence of fluorescent vesicles in microscopic analysis indicates 
endocytosis may be the main uptake mechanism employed. 
 Interestingly, confocal microscopy also revealed the presence of several bright 
cells which saturated the image in all three cell lines analyzed.  These cells all had 
characteristic signs of stress including rounding up and detachment from the plate.  
cPLA2 activation has previously been shown to be involved in apoptotic activation and 
shown to be required for tumor necrosis factor (TNFα) induced apoptosis (Enari et al. 
1996).  Lipid droplet accumulation, a characteristic of cancer cells exposed to apoptosis 
inducing anti-cancer agents (Delikatny et al. 2011), has also been linked to cPLA2 
activity (Gubern et al. 2008).  Whether the high fluorescence observed in microscopic 
images is a result of cPLA2 activity associated with apoptosis requires further 
investigation.  However, this result highlights the potential utility of DDAO arachidonate 
in the investigation of cell signaling and therapeutic response. 
 Finally, we sought to obtain a genetic knockout of cPLA2 through transfection 
with a cPLA2 targeted CRISPR/Cas9 vector.  Isolation and expansion of transfected cells 
resulted in a partial knockdown of cPLA2 expression.  Based on the mechanism of action 
for CRISPR, it is likely we obtained a mixed population of 100% knockout and fully 
cPLA2 expressing cells.  However, this mixed population did result in reduced DDAO 
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arachidonate fluorescence indicating that cPLA2 gene expression is correlated to probe 
activation.  Future work will include isolation of a 100% knockout cell line that will be 
used to determine the degree of non-specific activation involved in DDAO arachidonate 
activation. 
In summary, DDAO arachidonate appears to be specifically activated due to the 
actions of cPLA2 in breast cancer cell lines.  DDAO palmitate is not activated by cPLA2 
and therefore serves as a useful control for non-cPLA2 mediated cleavage, including the 
assessment of sPLA2 activity and aqueous hydrolysis.  Analysis of DDAO arachidonate 
in a panel of breast cancer cell lines indicates it may be useful for the in vivo molecular 
imaging of cPLA2 in triple negative breast cancer. 
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Chapter 5: In Vivo Activation of DDAO Arachidonate 
5.1 Introduction 
This Chapter explores the use of DDAO arachidonate for in vivo imaging of 
breast cancer and the evaluation of its potential as a contrast agent for NIR fluorescence 
guided surgery.  In vivo molecular imaging of cancer allows for the phenotypic and 
genotypic analysis of cancer while also providing anatomical tumor location. In a 
research setting, this allows for the assessment of tumor biology while also providing a 
model for the investigation of anti-cancer therapeutics (Willmann et al. 2008).  In a 
clinical setting, this allows for the real-time determination, monitoring and alteration of 
treatment protocols (Weissleder 2006). 
 Fluorescence guided surgery is a field rapidly gaining momentum for its ability to 
aid in the surgical resection of tumors.  Fluorescence guidance has been shown to reduce 
positive margins following resection and has been correlated to reduced risk of 
reoccurrence and metastasis (Nguyen and Tsien 2013).  Though promising, the majority 
of contrast agents which have been evaluated accumulate through the EPR effect and 
provide little functional information outside of vasculature disruption.  Activatable 
fluorophores have been shown to be capable of engineering specificity towards cancer 
markers and because they do not rely on accumulation they can generate a higher 
theoretical signal to noise (Rao, Dragulescu-Andrasi, and Yao 2007).   
 Improved contrast agents for breast cancer are desperately needed as the 
percentage of positive margins seen following surgery range from 5-49% based on the 
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study performed (Vahrmeijer et al. 2013).  cPLA2 has been shown to be a molecular 
target associated with breast cancer.  cPLA2 varies between subtypes with higher 
expression in basal-like triple negative breast cancer (Caiazza, Harvey, and Thomas 
2010). Elevated levels of cPLA2 in luminal-like breast cancer have been implicated in the 
development of resistance to hormonal therapy.  In support of this, luminal-like breast 
cancer patients with elevated cPLA2 had a statistically decreased rate of overall survival 
(Caiazza et al. 2011).  Therefore, activatable fluorophores targeted towards cPLA2 may 
prove useful in the surgical resection of breast cancer and the discernment of aggressive 
breast cancer from less aggressive forms in real-time. 
In Chapter 4, we identified DDAO arachidonate as an activatable fluorophore 
with specificity towards cPLA2.  In this chapter, we explore DDAO arachidonate for its 
use in the in vivo imaging of breast cancer.  We first explore the effects of systemic 
delivery of DDAO arachidonate.  Next we compare different tumor tissues for activation 
in ex vivo fluorescence studies.  Final we explore DDAO arachidonate in a surgical 
model through i.p. injections close to the tumor site. 
5.2 Results 
4175-Luc+ breast cancer cells were previously derived from MDA-MB-231 cells 
through harvesting and re-culturing of a lung metastasis from mice bearing tumor 
xenografts (Minn et al. 2005).  As a result, 4175-Luc+ breast cancer cells grow readily in 
mice and metastasize to lung. We have shown that 4175-Luc+ cells have high levels of 
cPLA2 and can activate DDAO arachidonate but not the DDAO palmitate control probe.  
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In order to assess the efficacy of DDAO arachidonate in vivo, 4175-Luc+ cells were 
grown as tumor xenografts in the hind right flank of athymic mice.   
Following the establishment of a palpable tumor, mice were switched to a low 
fluorescence chow (LabDiet 5V02) for 48 hours to reduce background fluorescence. 
DDAO arachidonate or DDAO palmitate (40 nmol) was injected in egg 
phosphatidylcholine liposomes (MF 0.05).  Fluorescence images (ex/em: 640/680) were 
acquired over 48 hours (Figure 5.1).  The results show that high fluorescence is 
observable throughout the entire mouse making discernment of tumor fluorescence 
Figure 5.1. Challenges of whole body fluorescence imaging.  Mice bearing 4175-Luc+ tumor 
xenografts were injected i.v. with 40 nmol of DDAO arachidonate containing liposomes (MF 0.05).  
Fluorescence is shown with time (ex/em: 640/680).  High background fluorescence is seen throughout the 
mouse which decreases slightly up to 48 hours. 
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difficult.  This initial result highlights the challenges associated with whole body 
fluorescence imaging.  DDAO fluorescence lies on the lower wavelength edge of the NIR 
window, where there may still be significant absorption from tissue.  In addition, tissue 
auto-fluorescence from elastin, collagen, and other endogenous biological fluorophores is 
high at wavelengths less than 600 nm and the tails of the emission spectra may overlap 
with DDAO fluorescence (Hilderbrand and Weissleder 2010).  Finally, we have shown in 
vitro that pancreatic sPLA2 GIB can activate both DDAO arachidonate and DDAO 
palmitate.  As a result, probe activation by sPLA2 GIB in the small intestines can occur 
resulting in signal overlap with surrounding tissue, increasing overall background. 
Spectral unmixing techniques have been developed for the separation of different 
fluorescent signals in vivo based on their characteristic spectra (Xu and Rice 2009).  By 
imaging fluorophores separately using various different emission and/or excitation filters, 
characteristic fluorescence spectra can be generated and saved for each fluorophore.  In 
vivo, these spectra can be applied to images with multiple fluorophores containing 
overlapping emission spectra in order to unmix the individual fluorescence signals.  This 
technique can be used to separate auto-fluorescence from actual signal, increasing 
detection specificity. 
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Figure 5.2. Whole body fluorescence imaging of DDAO arachidonate with spectral unmixing.  A) 
Mice bearing 4175-Luc+ tumor xenografts were injected i.v. with 40 nmol of DDAO arachidonate 
containing liposomes (MF 0.05).  Fluorescence is shown with time (ex/em: 640/680) using spectral 
unmixing post-processing to remove auto-fluorescence.  The tumor can be seen in the bottom right flank 
of the mouse indicated with an arrow.  B) Quantification of tumor fluorescence with time. 
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A filter scan was performed using two excitation filters (570 and 640 nm) and a 
series of emission filters separated by 20 nm for each excitation (excitation 570 nm: 
emission 620 - 780 nm; excitation 640 nm: emission 680 - 780 nm).  A spectral signal 
was acquired for DDAO in a 1.5 mL Eppendorf in PBS, pH 7.4, and auto-fluorescence 
using a dorsal facing mouse with no treatment.  Using the PerkinElmer LivingImage 
software, these spectra were applied to the images in Figure 5.1 and an unmixed 
fluorescence image of DDAO arachidonate and palmitate was obtained (Figure 5.2).  
Spectral unmixing resulted in a substantial reduction in auto-fluorescence.  As expected, 
intestinal fluorescence was observed as a result of DDAO arachidonate or palmitate 
activation in the intestines.  Because this signal arises from DDAO fluorescence, it was 
not removed through spectral unmixing.  However, the location of the tumor far from the  
 
Figure 5.3. Biodistribution of DDAO arachidonate and DDAO palmitate.  A) Fluorescence (ex/em: 
640/680) of DDAO arachidonate in excised tissue.  B) Quantification of the radiant efficiency for excised 
tissue.  C) Expanded view of organ fluorescence with digestive organs removed. 
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intestinal fluorescence allows the tumor signal to be resolved.  As digestion of 
fluorophore occurs, it is passed further down the intestines, and the signals begin to 
overlap (seen most notably at 48 hours).  Regardless, tumor fluorescence can be observed 
from both DDAO arachidonate and DDAO palmitate fluorophores (n=3 DDAO 
arachidonate, n=2 DDAO palmitate).  This fluorescence was significantly higher for 
DDAO arachidonate fluorescence at 4 and 6 hours relative to DDAO palmitate 
fluorescence (p = 0.002 and 0.02, respectively).  This significance is lost at 24 and 48 
hours as both signals increase.   
Following the image acquisition at 48 hours, mice were euthanized and individual 
organs were excised, rinsed in PBS, and imaged for fluorescence (ex/em: 640/680 nm) 
(Figure 5.3).  As expected, strong fluorescence was observed in both the small and large 
intestines.  In addition, stomach fluorescence was shown to also be high.  Tumor 
fluorescence was observed from both DDAO arachidonate and DDAO palmitate and was 
Figure 5.4.  Elimination of DDAO arachidonate and DDAO palmitate.  A) Whole body spectrally 
unmixed fluorescence of ventral facing mice over 2 days following injection i.v. with 40 nmol of DDAO 
arachidonate.  B) Quantification of DDAO arachidonate and DDAO palmitate elimination through 
measurement of whole body fluorescence spectrally unmixed signal from ventral facing mice. 
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greater than other non-digestive organs 
analyzed.  Though not significant, DDAO 
arachidonate fluorescence was slightly 
greater than DDAO palmitate in excised 
organs at 48 h.  In analysis of other organs, 
DDAO arachidonate tumor fluorescence 
was significantly higher than heart, lungs, 
kidney, and muscle (p = 0.02, 0.03, 0.04, 
0.04, respectively).  DDAO palmitate 
trended towards higher fluorescence but 
was not significantly larger than any other 
organ.  The calculated tumor / muscle ratio 
of DDAO arachidonate was found to be 
significant and determined to be 2.14.  
In a separate study, whole body 
fluorescence imaging with spectral 
unmixing of ventral facing mice was conducted as a function of time following injection 
of either DDAO arachidonate (n = 4) or DDAO palmitate (n = 4) (Figure 5.4).  There was 
high variability of the total fluorescence between each mouse in this experiment leading 
to larger error bars in the data.  However, a common trend of significantly decreased 
fluorescence was observed at 24 hours relative to the maximum signal at 6 hours for 
Figure 5.5. Ex Vivo tumor painting.  Orthotopic 
4175-Luc+ tumors were excised from mice, sliced, 
and cultured ex vivo in DMEM (5% CO2, 37°C).  
DDAO arachidonate, DDAO palmitate, or saline 
was painted onto tumors and left to incubate 3 
hours.  Tumors were then imaged for fluorescence 
in the   LI-COR Pearl Impulse imaging system 
(700 nm channel). 
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DDAO arachidonate (p = 0.02).  Therefore the majority of probe was cleared within this 
time. 
Despite the ability to resolve tumor fluorescence with spectral unmixing, high 
background and intestinal fluorescence remained challenging.  Furthermore, the low 
tumor signal intensity at 48 hours compared to intestinal signal indicated a relatively low 
delivery of fluorophore to tumor.  In order to assess tumor activation of probe directly 
and to avoid issues of delivery and background fluorescence, ex vivo tumor painting 
studies were conducted.   
For these experiments, mice were injected orthotopically with 4175-Luc+ cells.  
Following the formation of a palpable tumor, mice were euthanized.  Tumor tissue (n=2) 
was excised, sliced into approximately 1 
mm thick sections for the appropriate 
number of conditions, and placed into 24 
well plates containing DMEM.  The tissue 
was placed at 37°C, 5% CO2 and 20 nmol 
of DDAO arachidonate, DDAO palmitate, 
or saline was pipetted evenly over the 
surface of the tumor.  The tumor was 
incubated for 3 hours, washed twice in 
PBS, and fluorescence was acquired in a 
LI-COR Pearl Impulse imaging system 
Figure 5.6.  Analysis of DDAO fluorescence in 
the LI-COR Pearl Impulse Imaging system (700 
nm channel).  DDAO was assessed for 
fluorescence in TRIS buffer at pH 7.4 and pH 5.  
Free buffer is shown as a control. 
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(700 nm channel) (Figure 5.5).  Significantly greater fluorescence from tumors (n =2) 
painted with DDAO arachidonate was observed compared to either DDAO palmitate or 
saline (p = 7 x 10
-6
 and 6.5 x 10
-6
 respectively).  A small activation was observed from 
DDAO palmitate, which was significant over saline control (p = 4.5 x 10
-4
).  Due to the 
non-optimal excitation wavelengths in the Pearl Impulse imaging system, fluorescence of 
DDAO was confirmed to be visible at pH 7.4 using this system (Figure 5.6). 
Expanding on this study, we analyzed the differences in activation between 4175- 
Figure 5.7. Ex Vivo Tumor Painting for comparison of breast cancer subtypes.  A) 4175-Luc+, MCF-
7, and non-inoculated mammary fat pad were excised from mice, sliced and cultured ex vivo.  20 nmol 
DDAO arachidonate containing liposomes (MF 0.05) were pipetted evenly onto the surface of tumors.  
Fluorescence (ex/em: 640/680) was acquired with time. B) The final fluorescence relative to the amount 
of tissue was quantitated. 
92 
 
 
Figure 5.8. Intraoperative study of DDAO arachidonate. A) 4175-Luc+ cells were inoculated 
into the lower left mammary fat pad and into the right shoulder. Following formation of a palpable 
tumor, 40 nmol of DDAO arachidonate containing egg phosphatidylcholine liposomes (MF 0.05) 
were injected i.p. directly under the tumor. After one hour the mice were euthanized, and dissected 
to reveal the peritoneal cavity. The entire cavity was washed 1x in PBS and fluorescence (ex/em: 
640/680) was acquired. White arrows indicate the location of tumor. B) The orthotopic tumor, 
tumor bearing mammary fat pat, non-inoculated mammary fat pad, and shoulder tumor xenograft 
were excised, rinsed in PBS and imaged for fluorescence (ex/em: 640/680). The experiment was 
repeated with MCF-7 luminal-like cells. The images are shown on the same vertical scale in the 
central Figure, and again on the right with the vertical scale expanded to optimize tumor 
fluorescence. 
 
93 
 
Luc+ (basal-like) and MCF-7 (luminal-like) orthotopic tumors.  MCF-7 cells require 
estrogen for growth.  Therefore, one week prior to tumor inoculation, mice were 
implanted subcutaneously with a slow release 17β-estradiol tablet.  Following 
development of palpable tumors, mice were euthanized.  Tumor and non-inoculated 
mammary fat pad (n = 3) were excised, sliced into approximately 1 mm thick sections for 
the appropriate number of conditions, and placed in DMEM at 37°C, 5% CO2.  DDAO 
arachidonate (20 nmol) was pipetted evenly over the surface of the tumor.  Fluorescence 
was imaged on the IVIS spectrum as a function of time (ex/em: 640/680) (Figure 5.7).  
Significant activation of DDAO arachidonate was observed in 4175-Luc+ tumor slices 
versus MCF-7 and mammary fat pad at 30 min (p = 0.002 and 0.04 respectively) and 1 
hour (p = 0.001 and 0.04 respectively). 
It appears evident that high activation of DDAO arachidonate can be achieved in 
triple negative breast cancer, however high background fluorescence following systemic 
injection has thus far limited our ability to unequivocally determine tumor fluorescence in 
vivo.  Unlike targeted fluorophores that rely on selective accumulation, DDAO 
arachidonate has the advantage that it can activate selectively in cancerous tissue.  
Therefore, during surgical resection it may be possible to paint DDAO arachidonate onto 
the tumor versus delivering i.v.  In order to explore this, we sought to develop an 
experimental model that could mimic this surgical painting.   
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Tumors were grown orthotopically in the lower mammary fat pad.  Shoulder 
tumor xenografts were also implanted on the opposing side of the mouse.  Following 21 
days of growth, 40 nmol of DDAO arachidonate containing liposomes (MF 0.05) were 
injected i.p. directly under the tumor in order to enhance delivery.  After one hour, mice 
(n = 3) were euthanized and the peritoneal cavity was exposed.  The cavity was washed 
with PBS to remove non-absorbed fluorophore and fluorescence (ex/em: 640/680) was 
acquired on the IVIS Spectrum (Figure 5.8).  Strong fluorescence from the area of the 
tumor was observed (Figure 5.8A).  Surgical resection of orthopic tumor, shoulder tumor 
xenograft, inoculated mammary fat pad, and non-inoculated mammary fat pad was 
Figure 5.9.  Biodistribution of DDAO arachidonate 1 hour following i.p. injection.  Organ 
distribution of DDAO arachidonate is shown in under “Mouse 1”.  A control mouse was injected with an 
equal volume of saline.  The  legend of organs is shown on the right. 
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performed.  Organs were washed in PBS and ex vivo fluorescence (ex/em: 640/680) 
indicated strong fluorescence from the orthotopic tumor, which was significantly greater 
than fluorescence from the inoculated mammary fat pad, non-inoculated mammary fat 
pad, and the shoulder tumor xenograft (outside the area of DDAO arachidonate injection) 
(p = 0.002, 0.001, 0.001, respectively) (Figure 5.8B).  One inoculated mammary fat pad 
was noted to display high fluorescence.  Repeating this experiment in mice bearing 
luminal-like orthotopic tumors (n = 2) revealed significantly less activation (p = 0.01).  
However, when viewed on an expanded scale, there was significant activation of MCF-7 
tumors seen versus non-inoculated and inoculated mammary fat pad (p = 0.009 and 0.01, 
respectively).  Comparison of individual organs following i.p. injection of DDAO 
arachidonate revealed high intestinal and stomach fluorescence as was observed 
previously.  This signal was also present in a non-treated control mouse (n = 1), 
suggesting chow (despite being low fluorescence) still contributes to background 
fluorescence (Figure 5.9). 
5.3 Discussion 
Following i.v. administration of DDAO arachidonate and DDAO palmitate 
control, we were able to visualize time dependent changes in tumor fluorescence. 
However, high background signal was apparent from fluorescence dispersed throughout 
the animal. This fluorescence appeared with strong intensity in the upper left abdominal 
quadrant, possibly due to stomach or intestinal fluorescence, which was confirmed in ex 
vivo analysis.  Several factors can decrease the ability to resolve fluorescence in vivo.  
Absorption due to hemoglobin is prevalent up until 650 nm where it begins to decrease 
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(Weissleder 2001).  DDAO arachidonate is optimal just above this wavelength and 
therefore it is possible we still face signal loss from hemoglobin absorbance.  Increased 
background can also result from auto-fluorescence of tissue, which is higher at lower 
wavelengths (Hilderbrand and Weissleder 2010).  Finally, chow fluorescence can 
increase background signal resulting in loss of detectable signal.  Though we attempt to 
minimize the contribution of chow by feeding mice a low fluorescence diet, it is possible 
this is still a contributing factor. 
 In vitro analysis in Chapter 4 showed that DDAO arachidonate and DDAO 
palmitate are activated readily by sPLA2 GIB.  Therefore, high fluorescence background 
in the digestive tract is also possible through activation by pancreatic phospholipases.  In 
support of this, whole body fluorescence does appear to decrease at 24 and 48 hours as 
probe is eliminated. 
 Establishment of a spectral unmixing algorithm for the separation of DDAO 
fluorescence from auto-fluorescence was performed using the IVIS LivingImage 
software.  Upon application of the unmixing algorithm, we were able to reduce auto-
fluorescence.  Following removal of auto-fluorescence, high fluorescence remained from 
intestinal fluorescence.  Because DDAO fluorescence in the intestines will not be 
removed through an unmixing algorithm, this implies intestinal fluorescence is a result of 
activated DDAO, possibly through the actions of sPLA2 GIB, which is secreted into the 
small intestine from the pancreas.  Despite this, following adjustment for auto-
fluorescence, tumor fluorescence was visualized at two hours and increased over two 
days showing DDAO arachidonate can be used for tumor imaging in mice. 
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The effects of intestinal signal overlap must be considered in interpreting 
increased fluorescence in the tumor region of interest (ROI).  It was observed that 
intestinal fluorescence shifts in location over the course of two days, likely due to the 
elimination of the bulk probe.  By day 2, intestinal fluorescence was more closely 
overlapped with the tumor and could be the cause of the increase of signal observed. 
 Despite this, upon quantification of the tumor ROI, we showed that DDAO 
arachidonate fluorescence was significantly higher than DDAO palmitate fluorescence at 
4 and 6 hours post injection (p = 0.002 and 0.02, respectively).  This significance was lost 
at 24 and 48 hours, possibly due to overlap with intestinal fluorescence or slow activation 
of DDAO palmitate with time.  Both DDAO arachidonate and DDAO palmitate 
liposomes are expected to accumulate within tumors to the same degree and so we rely 
on differences in activation to visualize signal.  Therefore it is possible that at time points 
greater than 6 hours, DDAO palmitate that is present in the tumor but not activated, may 
activate through a number of mechanisms including sPLA2 and aqueous hydrolysis.  The 
higher rate of activation of DDAO arachidonate supports the hypotheses that this is due 
to increased cPLA2 within the tumor. 
 After 48 hours, organs were resected and analyzed.  Intestinal fluorescence was 
observed to be much higher than that of tumor fluorescence, showing most of the probe is 
being excreted by this time with relatively small amounts remaining in the tumor. 
Fluorescence activation in the intestine is likely a result of the actions of sPLA2 GIB.  
Interestingly, high fluorescence was also observable in the stomach.  Though it is 
possible that intestinal reflux or fecophagy could contribute to probe accumulation in the 
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stomach, the low pH of the stomach should minimize this fluorescence signal.  Chow 
fluorescence may be an additional contributing factor to the high fluorescence seen in 
stomach and intestines.  Analysis of tumor fluorescence with non-digestive organs 
showed significant activity from DDAO arachidonate tumor fluorescence compared to 
other organs (p = 0.02, 0.03, 0.04, 0.04 for heart, lungs, kidney, and muscle respectively), 
but not for DDAO palmitate.  However, fluorescence intensity was low for all organs and 
after 48 hours no significance was seen between DDAO arachidonate and DDAO 
palmitate.  These results indicate effective probe removal and relatively low tumor 
delivery combined with non-selective activation with time.  
 Using ex vivo tumor painting experiments we were able to show that significant 
activation of DDAO arachidonate versus DDAO palmitate was achievable in tumor tissue 
(p = 7x 10
-6
).  Furthermore, activity was observed on both the IVIS and Pearl Impulse 
imaging systems, which is important for future research utilizing DDAO arachidonate.   
A significant difference in activation could also be seen between basal-like and luminal-
like tumors (p = 0.001).  In addition, activation was significantly greater in basal-like 
tumors compared to healthy mammary fat pad (p = 0.04).  These data indicate that if the 
problems associated with delivery and high background can be addressed, DDAO 
arachidonate could be a highly useful contrast agent for the guided surgical resection of 
triple negative breast cancer. 
 Because DDAO arachidonate is activatable, i.v. injection may not be necessary in 
a surgical procedure.  Instead, similar to the ex vivo tumor painting experiments 
performed, DDAO arachidonate could be painted onto tissue in the operating room.  This 
99 
 
would reduce the high background fluorescence seen during i.v. injection.  Since rapid 
activation in ex vivo studies was observed, it is likely that visualization of tumor 
fluorescence would be possible at a much earlier time point using painting compared to 
i.v. injection.   
 To test this in a model system, we inoculated mice with 4175-Luc+ cells in the 
lower left mammary fat pad that lays in close proximity to the peritoneal cavity.  We then 
injected probe i.p. directly under the tumor.  We euthanized mice after just 1 hour, 
exposed the peritoneal cavity and looked for fluorescence activation.  Using this 
procedure, we observed high fluorescence in the tumor area relative to surrounding 
cavity.  Dissection of individual organs revealed that the tumor activated probe 
significantly compared to surrounding mammary fat pad (p = 0.002).  One mouse 
displayed high fluorescence from the healthy portion of the inoculated mammary fat pad 
(albeit lower than tumor fluorescence).  Whether this fluorescence is a result of residual 
tumor or alternative mechanisms requires further analysis.  However, this highlights the 
potential use of DDAO arachidonate as a surgical guide to ensure complete recession of 
tissue with high cPLA2 activity.  In this experiment, a shoulder tumor xenograft lying far 
from the area of injection was also analyzed and shown to have significantly lower 
fluorescence (p = 0.001).  We repeated this experiment in mice using the luminal-like 
MCF-7 cell line.  Unlike the 4175-Luc+ tumors, MCF-7 tumors gave significantly less 
activation in comparison (p = 0.01).  However, when analyzing tumor and healthy 
mammary fat pad a significant difference could still be observed (p = 0.01), suggesting 
MCF-7 tumors do activate DDAO arachidonate, albeit at a much lower rate than that of 
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4175-Luc+ tumors.  Analysis of all organs revealed high digestive fluorescence as 
observed previously.  However, high levels of digestive fluorescence were also observed 
in control mice.  Therefore, we can contribute observed digestive fluorescence partially to 
chow fluorescence.  Because our measurements take place after only 1 hour of 
incubation, it is likely that intestinal signal due to probe activation would increase with 
time as observed previously. 
Together, we conclude that DDAO arachidonate is a promising fluorophore for 
the imaging of cancerous tissue in vivo and is worthy of further investigation for its use as 
a contrast agent in NIR fluorescence guided surgery.  DDAO arachidonate should be used 
topically during surgery to visualize tumor margins and not injected i.v..  Though 
alternative delivery vehicles could be explored to enhance tumor delivery, topical 
delivery would also reduce the amount of probe needed, thus reducing potential systemic 
side effects, and decrease the wait time needed for optimal fluorescence.  Furthermore, 
our results suggest DDAO arachidonate would be most useful in the NIR fluorescence 
guided surgery of basal-like breast cancer.  However, cPLA2 activity has been suggested 
to vary in luminal-like cancers with increased expression being correlated with higher 
probability of developing resistance to estrogen receptor therapy (Caiazza et al. 2011).  
Therefore, use of DDAO arachidonate may be useful in staging luminal-like cancers and 
serve as an indicator for patients who may eventually develop resistance.  Finally, 
because cPLA2 is associated with more aggressive breast cancer, DDAO arachidonate 
may also be useful in analysis of tumor heterogeneity, separating more aggressive from 
less aggressive tumor areas. 
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CHAPTER 6: Conclusions and Future Directions 
6.1 Conclusions and Potential Applications 
Despite numerous discoveries related to the treatment of breast cancer, it remains 
a disease with high prevalence and cancer related mortality in women (DeSantis et al. 
2014).  Increasing the armamentarium of available therapeutics along with developing 
more sensitive imaging methods to identify and characterize breast cancer at an early 
stage are both critical to increasing cure rates.  Molecular based therapeutics have 
emerged that target unique molecular signatures of breast cancer through both traditional 
small molecule compounds and antibody-based therapeutics.  Despite this, surgical 
intervention remains the first line of defense for the treatment of breast cancer and the 
accuracy of surgery has been shown to correlate closely with the probability of 
reoccurrence and metastasis (Singletary 2002).  Methods of improving surgical resection 
are therefore vital to the continued treatment of this disease. 
 Within this dissertation, we introduced a novel activatable fluorophore, DDAO 
arachidonate, selective to the breast cancer associated protein, cPLA2.  Through a series 
of in vitro and in vivo studies we have evaluated this probe’s specificity for cPLA2 and 
for its ability to serve as a molecular imaging agent in breast cancer.  Our results indicate 
several advantages and potential limitations to the use of DDAO arachidonate for NIR 
fluorescence guided surgery.   In addition, our studies open the door for future research of 
cPLA2 activity in cancer and other diseases using DDAO arachidonate.  However, our 
results also identify areas of concern, which will be a focus in the future design of 
activatable fluorophores. 
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 The use of activatable probes in NIR fluorescence guided surgery deserves future 
study.  We have shown a high ability to distinguish healthy from cancerous tissue using 
DDAO arachidonate.  In addition, we have shown the ability to differentiate breast cancer 
subtypes with this probe, with higher activation observed in more aggressive cancer.  
Therefore, the intraoperative use of DDAO arachidonate may be able to accurately 
delineate tumor margins in real-time while providing functional information on variations 
in tissue heterogeneity. 
 DDAO arachidonate activation was shown to correlate closely with cPLA2 
expression.  Despite this, it was also shown that DDAO arachidonate is susceptible to 
aqueous hydrolysis, sPLA2 GIB mediated hydrolysis, and possible activation through 
unidentified sources.  In a research setting, we proposed the use of DDAO palmitate as a 
control probe to account for non-cPLA2 mediated cleavage.  However, for the potential 
use of DDAO arachidonate in clinical settings, this may be a confounding issue.  This is 
especially evident when administered i.v.  We observed high background fluorescence, 
partially due to activation outside the area of the tumor, especially in the digestive tract.  
In addition, we saw relatively low tumor accumulation with respect to probe clearance 
with the maximum measurable cPLA2 signal at 4 and 6 hours after administration.  This 
presents additional potential problems as the higher amounts of time necessary to 
generate signal increases the likelihood of non-cPLA2 mediated cleavage. 
 DDAO arachidonate is an activatable fluorophore, dependent on enzymatic 
cleavage for the generation of signal.  Unlike non-specific and targeted fluorophores, 
DDAO arachidonate does not depend to the same extent on tumor accumulation for 
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enhanced signal/noise.  This allows for the possible topical application of DDAO 
arachidonate in a surgical setting.  This would reduce the problems observed with non-
specific activation as less time would be needed between administration and 
visualization.  In addition, topical application would reduce the amount of probe needed 
to generate contrast thus limiting potential systemic side effects, which might occur 
through i.v. administration of larger concentrations.  For these reasons, we believe this 
mechanism of activatable fluorescence is of high value and should be utilized in the 
design of future contrast agents for NIR fluorescence guided surgery. 
Figure 6.1. Effects of anti-cancer drug treatment on cPLA2 activation.  A) MCF-7 cells were treated 
with 10 µM 5-fluorouracil, 40 µM etoposide, 10 mM phenylbutryate, or DMSO control for 12 hours.  
DDAO arachidonate activation was plotted with time.  B) Relative cPLA2 activity was calculated at 150 
min by adjusting DDAO arachidonate activation for non-specific cleavage measured with DDAO 
palmitate.   
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6.2 cPLA2 Activation During Apoptosis  
 In our attempts to define the specificity of DDAO arachidonate, we have made 
several observations related to the function of cPLA2, which warrant further 
investigation.  In confocal microscopy experiments presented in Chapter 4, we showed  
subcellular activation of DDAO arachidonate in various cell lines.  It was noted that in all 
cell lines analyzed, there were a small percentage of cells that gave much higher 
fluorescence than the general population.  These cells were all similar in morphology in 
that they were rounded up and beginning to detach from the tissue culture plastic, a 
characteristic of stressed or early apoptotic cells.   
 cPLA2 has been previously shown to be required in TNF-α induced apoptosis 
(Enari et al. 1996).  Furthermore, cPLA2 has been implicated in the formation of lipid 
droplets, which form in the early stages of the apoptotic response to anti-cancer therapy 
(Gubern et al. 2008, Delikatny et al. 2011, Guijas et al. 2014).  Therefore, if the 
fluorescence that was observed in confocal microscopy was a result of cPLA2 activation 
as part of the apoptotic process, then DDAO arachidonate may prove to have some utility 
in measuring tumor response to therapy.  Furthermore, if the high level of fluorescence 
activation seen in cellular studies translates to apoptosis in tumor bearing mice, some of 
the issues of signal to noise outlined earlier would be reduced. 
 In a preliminary study, we analyzed three apoptosis inducing agents for their 
effect on DDAO arachidonate activation.  We chose the MCF-7 cell line for analysis as it 
contains the lowest levels of cPLA2 and therefore offers the greatest potential for 
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increased signal generation.  MCF-7 cells were plated in 96-well black wall, clear bottom 
plates at 2.5 x 10
5
 cells / mL in 100 µL media 24 hours prior to drug treatment.  12 hours 
prior to experiment, the media was replaced with phenol red- and FBS-free media 
containing 10 µM 5-fluorouracil, 40 µM etoposide, or 10 mM phenylbutyrate.  Drug 
concentrations for 5-fluorouracil and etoposide were chosen based on previously reported 
literature values (Hernandez-Vargas et al. 2006, Alpsoy, Yasa, and Gunduz 2014).  Drug 
concentrations for phenylbutyrate was chosen based on previous performed toxicity 
studies of the prostate cancer cell line, DU145 (Milkevitch et al. 2005, Milkevitch et al. 
2007, Milkevitch, Beardsley, and Delikatny 2010).  To initiate the assay, 10 µL of 
DDAO arachidonate or DDAO palmitate in liposomes (MF 0.05) were added to each 
well.  Fluorescence was acquired with time and relative cPLA2 activity was calculated 
(Figure 6.1A and B).  Significant enhancement of cPLA2 activity was observed following 
administration of 5-fluorouracil, etoposide, and phenylbutyrate (p = 0.02, 0.003, 0.0004, 
respectively).  5-Fluorouracil, etoposide, and phenylbutyrate gave a 1.2, 1.3, and 2 fold 
increase in activity, respectively, when compared to control. Together, this provides 
further evidence for the role of cPLA2 in apoptosis and supports further investigation of 
DDAO arachidonate for the in vivo imaging of tumor response to therapy. 
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6.3 cPLA2 Involvement In Alternative Disease Models 
DDAO arachidonate shows promise in its potential to serve as a contrast agent for 
fluorescence guided surgery in breast cancer.  We have focused on breast cancer within 
this thesis for reasons including relatively high light penetration in breast tissue and 
variations of cPLA2 expression levels related to breast cancer subtype.  However, cPLA2 
overexpression is not unique to the breast and has been observed in other cancers.  In 
non-small cell lung cancer, cPLA2 expression was found to be elevated in relation to 
induction of the RAS oncogene (Heasley et al. 1997).  In addition, it has been shown that 
cPLA2 deficient mice have decreased lung tumor formation following urethane exposure 
Figure 6.2.  cPLA2 activity in lung cancer cell lines.  A) Immunoblot of cPLA2 and GAPDH (control) 
in 4175-Luc+ and three murine lung cancer lines.  B) Quantification of immunoblot showing expression 
relative to control.  C)  cPLA2 activity in 4175-Luc+ and TC1 cells as measured through activation of 
DDAO arachidonate (adjusted for DDAO palmitate activation) with respect to time.  Significant activity 
in TC1 vs. 4175-Luc+ cells was observed (p = 2.4 x 10
-7
) 
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(Meyer et al. 2004).   
In order to explore cPLA2 in a lung cancer model, we utilized 3 murine non-small 
cell lung cancer cell lines (LKR, LLC, and TC1), generously provided by Dr. Sunil 
Singhal in the Department of Surgery at the University of Pennsylvania.  Immunoblot of 
cPLA2, carried out by Sofya Osharovich, showed a remarkable elevation in expression in 
all lung cancer cell lines relative to 4175-Luc+.  Most dramatic was the TC1 line, which 
showed 9 fold increased expression of cPLA2 compared to the 4175-Luc+ cell line 
(Figure 6.2A and B).  To investigate the activity of cPLA2 within this cell line, 4175-
Luc+ and TC1 were plated at 2.5 x 10
5
 and 1.25 x 10
5
 cell/mL, respectively, in 100 µL 
media.  Plating concentrations were chosen to result in approximately 80% confluency at 
Figure 6.3.  Four step synthetic scheme for nitriloanthracenone. 
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time of analysis.  Following 24 hours of incubation, DDAO arachidonate or DDAO 
palmitate in liposomes (MF 0.05) were added to each well.  cPLA2 activity with time 
was determined and data was plotted by subtraction of DDAO palmitate fluorescence 
from DDAO arachidonate and scaled relative to the final number of cells (Figure 6.2C).  
A significant increase of fluorescence was observed from the TC1 cell line relative to the 
4175-Luc+ cell line (p = 2.4 x 10
-7
).  Therefore, we believe non-small cell lung cancer 
could be evaluated as a potential target for DDAO arachidonate mediated NIR 
fluorescence guided surgery. Our preliminary results suggest lung cancers may provide 
even higher levels of contrast than triple-negative breast cancer. 
6.4 Second-Generation Long-Wavelength Activatable Fluorophores 
Despite the success we have observed for DDAO arachidonate, signal to noise 
resulting from tissue absorbance, scattering, and auto-fluorescence remain problematic.  
Figure 6.4. Spectral properties of nitriloanthracenone. A) The addition of a nitrilo moiety to an 
existing tricyclic fluorophore induced an 80 nm bathochromic shift in the final product. B) Fluorescence 
(excitation 650 nm) results in fluorescence maximum at 680 nm and a large shoulder that persists to 750 
nm, suitable for in vivo NIR imaging. 
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DDAO lies at the edge of the NIR window and if fluorescence could be shifted farther 
into the NIR, higher signal could potentially be acquired.  Longer wavelength 
fluorophores tend to be large in size, which may prevent cPLA2 mediated cleavage as 
observed with naphthofluorescein diarachidonate.  In addition, the structures of NIR 
fluorophores typically do not allow for the caging of fluorescence.  Therefore, we sought 
to synthesize small tricyclic fluorophores with chemical modifications which might result 
in longer wavelength fluorescence emission. 
Through a four step synthesis, we introduced a nitrilo substitution to the central 
ring of an anthracene scaffold to generate a fluorophore called nitriloanthracenone 
(Figure 6.3).  Though similar in structure to DDAO, nitriloanthracenone displayed altered 
fluorescence properties, shifted further in the NIR region (Figure 6.4).  Addition of the 
nitrilo moiety (Figure 6.3 step 4), resulted in an 80 nm bathochromic shift of absorbance 
resulting in an excitation at 650 nm, and a maximum emission at 680 nm (Figure 6.4).  
The emission spectrum has a prominent shoulder which extended out to 750 nm.  The 
large Stokes shift in this fluorescence profile along with the extended emission 
wavelength into the NIR makes nitriloanthracenone an excellent potential platform for 
the design of NIR caged activatable fluorophores.  Further modifications will include the 
addition of dichloro and dimethoxy substituents ortho to the resonant active hydroxyl 
similar to DDAO.  We hypothesize that these substitutions will reduce non-specific and 
aqueous hydrolysis of the esterified derivatives, a necessary characteristic in the design of 
biological imaging agents.  Furthermore, dichloro and dimethoxy substituents may shift 
fluorescence further into the NIR to give enhanced in vivo properties.  Efforts are 
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currently underway to cage nitriloanthracenone to arachidonic acid in order to explore its 
use for cPLA2 imaging. 
6.5 Final Remarks 
In conclusion, we have supplied evidence for a new molecular imaging agent 
specific to cPLA2.  We believe this will prove to be a valuable platform for the 
exploration of the function of cPLA2 in disease progression.  In breast cancer, DDAO 
arachidonate warrants further investigation for its ability to aid in NIR fluorescence 
guided surgery.  The application of this probe to other purposes such as apoptotic 
imaging or the molecular imaging of lung cancer will become clearer as more studies are 
performed.  Finally, second generation fluorophores, with enhanced in vivo optical 
properties, offer the potential to greatly increase the capabilities of molecular imaging.  
Taken together, we believe the future of activatable fluorophores is bright. 
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